{"content":"<li class=\"n-box-item date-title\" data-end=\"1528171199\" data-start=\"1528084800\" data-txt=\"Monday, December 23, 2019\">Monday, June  4, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3361561\" data-ts=\"1528148814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361561-portola-pharma-ceo-lis-to-retire-sharesminus-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharma CEO Lis to retire; shares -2%</a></h4><ul>     <li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) <font color='red'>-1.9%</font> after-hours following news of the <a href=\"https://seekingalpha.com/pr/17182249-portola-pharmaceuticals-announces-retirement-ceo-bill-lis-2018\" target=\"_blank\">retirement of Bill Lis</a> as CEO and a a board member, effective Aug. 1.</li>     <li>John Curnutte and Mardi Dier are appointed interim co-presidents in addition to their current respective positions as Executive VP for Research and Development and CFO.</li>     <li>Lis joined PTLA in 2008 as chief business officer and COO and was appointed CEO in May 2010; he previously held positions at Scios, a Johnson &amp; Johnson company, and Millennium Pharmaceuticals.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361561\" data-linked=\"Portola Pharma CEO Lis to retire; shares -2%\" data-tweet=\"$PTLA - Portola Pharma CEO Lis to retire; shares -2% https://seekingalpha.com/news/3361561-portola-pharma-ceo-lis-to-retire-sharesminus-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3361561-portola-pharma-ceo-lis-to-retire-sharesminus-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361560\" data-ts=\"1528148284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANW\" target=\"_blank\">ANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361560-aegean-marine-plunges-47-amid-write-off-of-200m-receivable\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegean Marine plunges 47% amid write-off of $200M receivable</a></h4><ul>   <li>Microcap Aegean Marine (<a href='https://seekingalpha.com/symbol/ANW' title='Aegean Marine Petroleum Network Inc.'>OTC:ANW</a>) is seeing half its market value fall away in aftermarket trading following an after-hours update on its ongoing review that says it needs to <a href=\"https://seekingalpha.com/pr/17182235-aegean-marine-petroleum-network-inc-provides-update-financial-reporting-internal-review\" target=\"_blank\">write off $200M it's owed</a>.</li>    <li>The company had previously disclosed that its audit committee is reviewing matters relevant to its financials for the year ended Dec. 31, 2017.</li>    <li>\"Based on the preliminary findings of the review, the Audit Committee believes that approximately $200 million of accounts receivable owed to the Company at December 31, 2017 will need to be written off,\" the company says.</li>    <li>Those amounts are due from four counterparties.</li>    <li>The transactions that led to that $200M \"may have been, in full or in part, without economic substance and improperly accounted for in contravention of the Company&rsquo;s normal policies and procedures,\" it says.</li>    <li>Shares are <font color='red'>down 47.4%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361560\" data-linked=\"Aegean Marine plunges 47% amid write-off of $200M receivable\" data-tweet=\"$ANW - Aegean Marine plunges 47% amid write-off of $200M receivable https://seekingalpha.com/news/3361560-aegean-marine-plunges-47-amid-write-off-of-200m-receivable?source=tweet\" data-url=\"https://seekingalpha.com/news/3361560-aegean-marine-plunges-47-amid-write-off-of-200m-receivable\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>122&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361559\" data-ts=\"1528148194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NX\" target=\"_blank\">NX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361559-after-hours-gainers-losers-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (06/04/2018)</a></h4><ul>     <li><b>Top gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/NX' title='Quanex Building Products Corporation'>NX</a>&nbsp;<font color='green'>+8.4%</font>. <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a>&nbsp;<font color='green'>+7.8%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+7.8%</font>. <a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>&nbsp;<font color='green'>+5.3%</font>. <a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='green'>+4.6%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='red'>-10.1%</font>. <a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a>&nbsp;<font color='red'>-7.1%</font>.&nbsp;&nbsp;<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a>&nbsp;<font color='red'>-3.8%.&nbsp;</font><a href='https://seekingalpha.com/symbol/CALX' title='Calix, Inc.'>CALX</a>&nbsp;<font color='red'>-2.7%</font>. <a href='https://seekingalpha.com/symbol/AROC' title='Archrock Inc.'>AROC</a>&nbsp;<font color='red'>-2.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361559\" data-linked=\"After Hours Gainers / Losers (06/04/2018)\" data-tweet=\"$NX $NX $EGY - After Hours Gainers / Losers (06/04/2018) https://seekingalpha.com/news/3361559-after-hours-gainers-losers-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361559-after-hours-gainers-losers-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361555\" data-ts=\"1528147378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361555-monsanto-deal-near-netflix-to-s-and-p-100-twitter-to-s-and-p-500-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">With Monsanto deal near, Netflix to S&amp;P 100; Twitter to S&amp;P 500 (updated)</a></h4><ul>   <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/719152_nflx1twtr5rgnx6.pdf?force_download=true\" target=\"_blank\">headed into the S&amp;P 100</a>, and Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) into the S&amp;P 500, Standard &amp; Poor's announces.</li>    <li>Both firms are replacing Monsanto (NYSE:<a href='https://seekingalpha.com/symbol/MON' title='Monsanto Company'>MON</a>) in the respective indexes, with Monsanto's acquisition by Bayer imminent.</li>    <li>In other moves, REGENXBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a>) will move into the SmallCap 600, to replace General Cable (NYSE:<a href='https://seekingalpha.com/symbol/BGC' title='General Cable Corporation'>BGC</a>). General Cable is set to be acquired by Prysmian Group.</li>    <li><a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> is <font color='green'>up 0.7%</font> after hours in what looks to be thin trading. Shares <font color='red'>declined 6.8%</font> today.</li>    <li>All moves are effective prior to Thursday's open.</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='red'>-0.2%</font>.</li><li><strong>Updated 5:27 p.m.:</strong>&nbsp;Twitter shares are <font color='green'>up 3.6%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361555\" data-linked=\"With Monsanto deal near, Netflix to S&amp;P 100; Twitter to S&amp;P 500 (updated)\" data-tweet=\"$NFLX $NFLX $TWTR - With Monsanto deal near, Netflix to S&amp;P 100; Twitter to S&amp;P 500 (updated) https://seekingalpha.com/news/3361555-monsanto-deal-near-netflix-to-s-and-p-100-twitter-to-s-and-p-500-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3361555-monsanto-deal-near-netflix-to-s-and-p-100-twitter-to-s-and-p-500-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361547\" data-ts=\"1528146013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361547-fda-oks-mylans-neulasta-biosimilar-shares-up-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Mylan&#39;s Neulasta biosimilar; shares up 5% after hours</a></h4><ul><li>Mylan N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) is up&nbsp;<font color='green'>5%&nbsp;</font>after hours on the news that the FDA has <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609805.htm\" target=\"_blank\">approved</a> its biosimilar of Amgen's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) Neulasta (pegfilgrastim), branded as Fulphila (pegfilgrastim-jmdb).</li></ul><div class=\"tiny-share-widget\" data-id=\"3361547\" data-linked=\"FDA OKs Mylan&#39;s Neulasta biosimilar; shares up 5% after hours\" data-tweet=\"$MYL $MYL $AMGN - FDA OKs Mylan&#39;s Neulasta biosimilar; shares up 5% after hours https://seekingalpha.com/news/3361547-fda-oks-mylans-neulasta-biosimilar-shares-up-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3361547-fda-oks-mylans-neulasta-biosimilar-shares-up-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361542\" data-ts=\"1528145122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361542-deciphera-readies-stock-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deciphera readies stock offering; shares down 7% after hours</a></h4><ul><li>Deciphera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a>) is down&nbsp;<font color='red'>7%</font>&nbsp;after hours in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1654151/000119312518183237/d592942ds1.htm\" target=\"_blank\">preliminary prospectus</a> for a public offering of 3.75M shares of common stock. Price and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361542\" data-linked=\"Deciphera readies stock offering; shares down 7% after hours\" data-tweet=\"$DCPH - Deciphera readies stock offering; shares down 7% after hours https://seekingalpha.com/news/3361542-deciphera-readies-stock-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3361542-deciphera-readies-stock-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361540\" data-ts=\"1528144927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATB\" target=\"_blank\">CATB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361540-catabasis-pharma-files-for-30m-equity-offering-shares-off-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catabasis Pharma files for $30M equity offering; shares off 7% after hours</a></h4><ul><li>Thinly traded nano cap Catabasis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a>) is down&nbsp;<font color='red'>7%</font>&nbsp;after hours in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1454789/000104746918004247/a2235913zs-1.htm\" target=\"_blank\">preliminary prospectus</a> for a $30M offering of units, each consisting of one share of common stock and one warrant to purchase one share of common. Prices, volumes and terms have yet to be determined.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361540\" data-linked=\"Catabasis Pharma files for $30M equity offering; shares off 7% after hours\" data-tweet=\"$CATB - Catabasis Pharma files for $30M equity offering; shares off 7% after hours https://seekingalpha.com/news/3361540-catabasis-pharma-files-for-30m-equity-offering-shares-off-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3361540-catabasis-pharma-files-for-30m-equity-offering-shares-off-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361539\" data-ts=\"1528144926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDR\" target=\"_blank\">BDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361539-blonder-tongue-jumps-20-discloses-end-of-sale-leaseback-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blonder Tongue jumps 20%; discloses end of sale-leaseback deal</a></h4><ul>    <li>Nanocap TV signal equipment maker Blonder Tongue Laboratories (NYSEMKT:<a href='https://seekingalpha.com/symbol/BDR' title='Blonder Tongue Laboratories, Inc'>BDR</a>) ran itself to a <font color='green'>19.9% gain</font> today on more than quadruple average volume.</li>    <li>The stock touched a new 52-week high of $2.20 before a heavy sell-off in the last 10 minutes of NYSE trading brought it to $1.63.</li>    <li>Minutes ago, the company <a href=\"https://seekingalpha.com/filing/4053401\" target=\"_blank\">filed an 8-K</a> saying that on May 29 it got notice from Mountainblue Jake Brown Realty that it was terminating an agreement to buy Blonder Tongue's manufacturing facility in Old Bridge, N.J.</li>    <li>Blonder Tongue had planned to sell and lease back the facility for a five-year term. It says it will still look to sell the property, either outright or as a sale/leaseback.</li>    <li>The company manufactures signal encoding, transcoding, digital transport and broadband product solutions at the Old Bridge facility as well as through a contract manufacturer in China.</li>    <li>Shares are <font color='green'>up another 3.1%</font> after hours, to $1.68.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361539\" data-linked=\"Blonder Tongue jumps 20%; discloses end of sale-leaseback deal\" data-tweet=\"$BDR - Blonder Tongue jumps 20%; discloses end of sale-leaseback deal https://seekingalpha.com/news/3361539-blonder-tongue-jumps-20-discloses-end-of-sale-leaseback-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3361539-blonder-tongue-jumps-20-discloses-end-of-sale-leaseback-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361535\" data-ts=\"1528144492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNDI\" target=\"_blank\">KNDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361535-kandi-technologies-plummets-in-late-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kandi Technologies plummets in late action</a></h4><ul><li>Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) plummeted in late day action on a move that Bloomberg reports is tied to a large block trade.</li><li>The block of 209K shares was unloaded at $3.85 to put downward pressure on the EV player.</li><li>Volume on Kandi was sky-high today with over 2.5M shares being swapped.</li><li>Kandi&nbsp;<font color='red'>closed down 28.7%</font>&nbsp;to $3.85.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361535\" data-linked=\"Kandi Technologies plummets in late action\" data-tweet=\"$KNDI - Kandi Technologies plummets in late action https://seekingalpha.com/news/3361535-kandi-technologies-plummets-in-late-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3361535-kandi-technologies-plummets-in-late-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361533\" data-ts=\"1528144253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBUX\" target=\"_blank\">SBUX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361533-starbucks-schultz-steps-down-chairman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starbucks&#39; Schultz steps down as chairman</a></h4><ul> <li>Howard Schultz announces his departure as executive chairman of Starbucks (NASDAQ:<a href='https://seekingalpha.com/symbol/SBUX' title='Starbucks Corporation'>SBUX</a>) in June. He will also step down from the board after a 40-year career at the company.</li><li>Starbucks grew from 11 stores to over 28K under his leadership.</li>     <li>Schultz will be honored as chairman emeritus of the company.</li><li>SBUX  <font color='red'>-1.262%</font> after hours to  $56.35.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17182222-iconic-leader-visionary-entrepreneur-howard-schultz-bid-farewell-starbucks-nearly-40-years\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3361533\" data-linked=\"Starbucks&#39; Schultz steps down as chairman\" data-tweet=\"$SBUX - Starbucks&#39; Schultz steps down as chairman https://seekingalpha.com/news/3361533-starbucks-schultz-steps-down-chairman?source=tweet\" data-url=\"https://seekingalpha.com/news/3361533-starbucks-schultz-steps-down-chairman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>144&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361532\" data-ts=\"1528144237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVXL\" target=\"_blank\">AVXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361532-anavex-adds-to-rally-up-32\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anavex adds to rally, up 32%</a></h4><ul><li>Thinly traded micro cap Anavex Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a>) was up on a solid 16x surge in volume. Shares have rallied ~90% since the company reported FQ2 results on May 10.</li><li>Lead candidate is Phase 2-stage ANAVEX 2-73 for Parkinson's disease dementia.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3346081-anavex-readies-mid-stage-study-lead-candidate-pdd-shares-ahead-2-percent-premarket\" target=\"_blank\">Anavex readies mid-stage study of lead candidate in PDD; shares ahead 2% premarket</a> (April 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361532\" data-linked=\"Anavex adds to rally, up 32%\" data-tweet=\"$AVXL - Anavex adds to rally, up 32% https://seekingalpha.com/news/3361532-anavex-adds-to-rally-up-32?source=tweet\" data-url=\"https://seekingalpha.com/news/3361532-anavex-adds-to-rally-up-32\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361530\" data-ts=\"1528144123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LIVX\" target=\"_blank\">LIVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361530-livexliveplus-24_9-dawson-james-sees-double-digit-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LiveXLive +24.9% as Dawson James sees double-digit upside</a></h4><ul>   <li>Festival/event video streamer LiveXLive Media (NASDAQ:<a href='https://seekingalpha.com/symbol/LIVX' title='LiveXLive Media, Inc.'>LIVX</a>) was a top gainer among Nasdaq issues today, its second recent spike after a relatively ho-hum ride since its IPO.</li>    <li>Shares jumped May 17 from $4.225 to $6.95 on no particular reason. The company then announced a partnership with Montreux Jazz Festival later that weekend.</li>    <li>Shares closed today <font color='green'>up 24.9%</font> to $5.56 after an initiation by Dawson James at Buy, with a $7 price target, implying 26% upside from today's close.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361530\" data-linked=\"LiveXLive +24.9% as Dawson James sees double-digit upside\" data-tweet=\"$LIVX - LiveXLive +24.9% as Dawson James sees double-digit upside https://seekingalpha.com/news/3361530-livexliveplus-24_9-dawson-james-sees-double-digit-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3361530-livexliveplus-24_9-dawson-james-sees-double-digit-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361529\" data-ts=\"1528143995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMAR\" target=\"_blank\">SMAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361529-smartsheetminus-2-despite-q1-beats-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smartsheet -2% despite Q1 beats, upside guidance</a></h4><ul><li>        Smartsheet (NYSE:<a href='https://seekingalpha.com/symbol/SMAR' title='Smartsheet'>SMAR</a>)&nbsp;<font color='red'>drops 2%</font>&nbsp;aftermarket on Q1 results that beat EPS and revenue estimates with a 63% Y/Y growth. This was the company&rsquo;s first earnings report since the IPO in late April.</li><li>               Q2 guidance has revenue from $38.5M to $39.5M (consensus: $37.23M) and EPS from -$0.14 to -$0.13 (consensus: -$0.14). &nbsp;&nbsp;</li><li>               Upside FY19 guidance has revenue of $159M to $162M (consensus: $155.06M) and EPS of -$0.59 to -$0.56 (consensus: -$0.61).&nbsp;</li><li>               Key metrics: Operating cash flow, -$8.2M ; FCF, -$9.7M; domain-based customers, 75,642; all customers with annualized contract values of $5K+, 4,349 (+78% Y/Y); average ACV per domain-based customer, $1.808 (+47%); total operating expenses, $42M; cash and equivalents, $49.7M.&nbsp;</li><li>               Earnings call is scheduled for 4:30 PM Eastern with a webcast available <a href=\"https://investors.smartsheet.com/home/default.aspx\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17182170-smartsheet-inc-announces-first-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361516-smartsheet-beats-0_06-beats-revenue\" target=\"_blank\">Smartsheet beats by $0.06, beats on revenue</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361529\" data-linked=\"Smartsheet -2% despite Q1 beats, upside guidance\" data-tweet=\"$SMAR - Smartsheet -2% despite Q1 beats, upside guidance https://seekingalpha.com/news/3361529-smartsheetminus-2-despite-q1-beats-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3361529-smartsheetminus-2-despite-q1-beats-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361528\" data-ts=\"1528143908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361528-ascena-retail-lower-after-weak-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail lower after weak profit guidance</a></h4><ul> <li>Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>) trades lower after reporting Q3 numbers and updating guidance.</li><li>The company reported a FQ3 EPS loss of $0.08.</li><li>Gross margin fell 190 bps to r 58.7% of sales during the quarter due partially to performance in the company's value fashion segment.</li><li>CEO update: \"Our third quarter results reflected a soft start in       February, with sequential improvement over the combined March / April       period. Another strong quarter at Justice was offset by continued       challenges at our Value segment, particularly at dressbarn.\"</li><li>Looking ahead, the retailer sees a FQ4 loss larger than the consensus estimate from analysts.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17182160-ascena-retail-group-inc-reports-third-quarter-results-provides-guidance-fourth-quarter-fiscal\" target=\"_blank\">Press Release</a></li><li>ASNA&nbsp;<font color='red'>-1.91%&nbsp;</font>AH.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361528\" data-linked=\"Ascena Retail lower after weak profit guidance\" data-tweet=\"$ASNA - Ascena Retail lower after weak profit guidance https://seekingalpha.com/news/3361528-ascena-retail-lower-after-weak-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3361528-ascena-retail-lower-after-weak-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361527\" data-ts=\"1528143606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361527-oil-prices-slide-near-two-month-lows-opec-seen-curbing-output-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil prices slide near two-month lows as OPEC seen curbing output cuts</a></h4><ul>     <li>Crude oil futures fell today, with U.S. WTI settling near a <a href=\"https://www.marketwatch.com/story/oil-prices-slip-as-investors-wait-for-opec-to-make-a-move-2018-06-04\" target=\"_blank\">two-month low</a>, as investors continue to sell in the face of growing U.S. production, possible global supply growth and nagging trade tensions.</li>     <li>July WTI settled <font color='red'>-1.6%</font> to 64.75/bbl, the lowest finish for a front-month contract since April 9, with August Brent <font color='red'>-2%</font> to $75.29/bbl, the lowest since May 8.</li>     <li>&ldquo;The catalyst for this recent pullback in oil was the mention of revisions to the currently capped&rdquo; production policy by Saudi Arabia and Russia, says <em>Sevens Report</em> co-editor Tyler Richey.</li>     <li>&ldquo;If they were to increase production, then the other OPEC and non-OPEC producers would follow suit so they each maintain their market share, and <a href=\"https://www.wsj.com/articles/oil-ticks-lower-as-market-awaits-opecs-next-move-1528107824\" target=\"_blank\">once again flood the market with oil</a>,\" says Andy Lipow of Lipow Oil Associates.</li>     <li>\"We are <a href=\"https://www.cnbc.com/2018/06/03/oil-markets-record-us-output-and-higher-opec-supplies-in-focus.html\" target=\"_blank\">breaking key levels of support</a> now,\" says Phillip Streible, analyst at RJO Futures in Chicago. \"Once we started taking out $65.50 or  so, it really started to accelerate.\"</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/GUSH' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3x Shares ETF'>GUSH</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/DRIP' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares ETF'>DRIP</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/NDP' title='Tortoise Energy Independence Fund'>NDP</a>, <a href='https://seekingalpha.com/symbol/PXE' title='Invesco Dynamic Energy Exploration & Production Portfolio ETF'>PXE</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Invesco S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='Invesco Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/NANR' title='SPDR S&P North American Natural Resources ETF'>NANR</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a>, <a href='https://seekingalpha.com/symbol/USOU' title='United States 3x Oil Fund'>USOU</a>, <a href='https://seekingalpha.com/symbol/USOD' title='United States 3x Short Oil Fund ETF'>USOD</a>, <a href='https://seekingalpha.com/symbol/FTXN' title='First Trust Nasdaq Oil & Gas ETF'>FTXN</a>, <a href='https://seekingalpha.com/symbol/JHME' title='John Hancock Multifactor Energy ETF'>JHME</a>, <a href='https://seekingalpha.com/symbol/UBRT' title='Credit Suisse AxelaTrader 3x Long Brent Crude Oil ETN'>UBRT</a>, <a href='https://seekingalpha.com/symbol/ERYY' title='Direxion Daily Energy Bear 1x Shares ETF'>ERYY</a>, <a href='https://seekingalpha.com/symbol/DBRT' title='Credit Suisse AxelaTrader 3x Inverse Brent Crude Oil ETN'>DBRT</a>, <a href='https://seekingalpha.com/symbol/ERGF' title='iShares Edge MSCI Multifactor Energy ETF'>ERGF</a>, <a href='https://seekingalpha.com/symbol/OILD' title='ProShares UltraPro 3x Short Crude Oil ETF'>OILD</a>, <a href='https://seekingalpha.com/symbol/OILU' title='ProShares UltraPro 3x Crude Oil ETF'>OILU</a>, <a href='https://seekingalpha.com/symbol/USAI' title='American Energy Independence ETF'>USAI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3361527\" data-linked=\"Oil prices slide near two-month lows as OPEC seen curbing output cuts\" data-tweet=\"$USO $XLE $OIL - Oil prices slide near two-month lows as OPEC seen curbing output cuts https://seekingalpha.com/news/3361527-oil-prices-slide-near-two-month-lows-opec-seen-curbing-output-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3361527-oil-prices-slide-near-two-month-lows-opec-seen-curbing-output-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361514\" data-ts=\"1528143598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTMX\" target=\"_blank\">CTMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361514-investors-unmoved-cytomxs-data-on-cxminus-072-shares-down-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors unmoved with CytomX&#39;s data on CX-072; shares down 16%</a></h4><ul><li>CytomX Therapeutics (<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='red'>-16.2%</font>) finished in the red today on more than a 4x surge in volume after it <a href=\"https://seekingalpha.com/pr/17181507-cytomx-therapeutics-presents-preliminary-clinical-proof-concept-data-probody-platform-cxminus\" target=\"_blank\">announced </a>two ASCO presentations this morning focused on lead candidate CX-072.</li><li>Preliminary results from the Phase 1/2 PROCLAIM-027 assessing lead candidate CX-072 alone and in combination with Bristol-Myers Squibb's Yervoy (ipilimumab) or Roche's Zelboraf (vemurafenib) in heavily pretreated patients with advanced solid tumors, showed a 15% response rate and 55% disease control rate.</li><li>In the Phase 1 dose-escalation portion, the maximum tolerated dose has not been reached. Most treatment-related adverse events were mild or moderate.</li><li>The company will host a conference call today at 5:00 pm CT to discuss the data.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357569-cytomx-6-percent-premarket-cxminus-072-data\" target=\"_blank\">CytomX up 6% premarket on CX-072 data</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361514\" data-linked=\"Investors unmoved with CytomX&#39;s data on CX-072; shares down 16%\" data-tweet=\"$CTMX - Investors unmoved with CytomX&#39;s data on CX-072; shares down 16% https://seekingalpha.com/news/3361514-investors-unmoved-cytomxs-data-on-cxminus-072-shares-down-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3361514-investors-unmoved-cytomxs-data-on-cxminus-072-shares-down-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361525\" data-ts=\"1528143460\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NX\" target=\"_blank\">NX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361525-quanex-building-products-beats-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quanex Building Products beats by $0.01, misses on revenue</a></h4><ul><li>Quanex Building Products (NYSE:<a href='https://seekingalpha.com/symbol/NX' title='Quanex Building Products Corporation'>NX</a>): Q2 EPS of $0.14 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $214.21M (+2.4% Y/Y) <font color='red'>misses by $0.6M</font>.</li><li>Shares <font color='green'>+2.71%</font>.</li><li><a href='https://seekingalpha.com/pr/17182218-quanex-building-products-announces-second-quarter-2018-results-reaffirms-full-year-2018'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3361525\" data-linked=\"Quanex Building Products beats by $0.01, misses on revenue\" data-tweet=\"$NX - Quanex Building Products beats by $0.01, misses on revenue https://seekingalpha.com/news/3361525-quanex-building-products-beats-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3361525-quanex-building-products-beats-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361515\" data-ts=\"1528142840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361515-coupa-software-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software beats by $0.10, beats on revenue</a></h4><ul><li>Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>): Q1 EPS of -$0.01 <font color='green'>beats by $0.10</font>.</li><li>Revenue of $56.35M (+37.0% Y/Y) <font color='green'>beats by $5.17M</font>.</li><li>Shares <font color='green'>+1.21%</font>.</li><li><a href='https://seekingalpha.com/pr/17182182-coupa-software-reports-financial-results-first-quarter-fiscal-2019'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3361515\" data-linked=\"Coupa Software beats by $0.10, beats on revenue\" data-tweet=\"$COUP - Coupa Software beats by $0.10, beats on revenue https://seekingalpha.com/news/3361515-coupa-software-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3361515-coupa-software-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361507\" data-ts=\"1528142385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFX\" target=\"_blank\">CFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361507-colfaxminus-3-after-bofa-merrill-cuts-to-underperform-from-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Colfax -3% after BofA Merrill cuts to Underperform from Buy</a></h4><ul>     <li>Colfax (<a href='https://seekingalpha.com/symbol/CFX' title='Colfax Corporation'>CFX</a> <font color='red'>-3%</font>) is lower after getting a <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11822106/bofa-downgrades-colfax-on-macro-volatility-howden-chall\" target=\"_blank\">double downgrade</a> to Underperform from Buy with a $32 price target, slashed from $46, at BofA Merrill Lynch, which expects below-average core growth with margins below the 15-percent target.</li>     <li>BAML says CFX is the most vulnerable in its portfolio to macro volatility and a strengthening U.S. dollar, particularly as it has the least North American exposure.</li>     <li>\"M&amp;A is at the core of CFX&rsquo;s growth strategy but CFX&rsquo;s discounted valuation limits its acquisition flexibility in the current environment of elevated acquisition multiples in the industrial space,\"&nbsp;BAML writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361507\" data-linked=\"Colfax -3% after BofA Merrill cuts to Underperform from Buy\" data-tweet=\"$CFX - Colfax -3% after BofA Merrill cuts to Underperform from Buy https://seekingalpha.com/news/3361507-colfaxminus-3-after-bofa-merrill-cuts-to-underperform-from-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3361507-colfaxminus-3-after-bofa-merrill-cuts-to-underperform-from-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361506\" data-ts=\"1528142269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNX\" target=\"_blank\">KNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361506-trade-worries-hit-trucking-names-and-rails\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trade worries hit trucking names and rails</a></h4><ul><li>There's more trade anxiety in the transportation sector today as tariff rhetoric flares up again.</li><li>Truckers and rails in particular are in a downswing.</li><li>Notable movers include Knight Transportation (<a href='https://seekingalpha.com/symbol/KNX' title='Knight-Swift Transportation Holdings Inc.'>KNX</a> <font color='red'>-6.1%</font>), ArcBest (<a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a> <font color='red'>-3.4%</font>), Old Dominion Freight Line (<a href='https://seekingalpha.com/symbol/ODFL' title='Old Dominion Freight Line, Inc.'>ODFL</a> <font color='red'>-3.4%</font>), USA Truck (<a href='https://seekingalpha.com/symbol/USAK' title='USA Truck, Inc.'>USAK</a> <font color='red'>-3.2%</font>), Landstar System (<a href='https://seekingalpha.com/symbol/LSTR' title='Landstar System, Inc.'>LSTR</a> <font color='red'>-3.1%</font>), YRC Worldwide (<a href='https://seekingalpha.com/symbol/YRCW' title='YRC Worldwide, Inc.'>YRCW</a> <font color='red'>-3.6%</font>), Union Pacific (<a href='https://seekingalpha.com/symbol/UNP' title='Union Pacific Corporation'>UNP</a> <font color='red'>-2.8%</font>), Norfolk Southern (<a href='https://seekingalpha.com/symbol/NSC' title='Norfolk Southern Corporation'>NSC</a> <font color='red'>-2.3%</font>) , Kansas City Southern (<a href='https://seekingalpha.com/symbol/KSU' title='Kansas City Southern'>KSU</a> <font color='red'>-1.7%</font>) and FreightCar America (<a href='https://seekingalpha.com/symbol/RAIL' title='FreightCar America, Inc.'>RAIL</a> <font color='red'>-2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3361506\" data-linked=\"Trade worries hit trucking names and rails\" data-tweet=\"$KNX $KNX $ARCB - Trade worries hit trucking names and rails https://seekingalpha.com/news/3361506-trade-worries-hit-trucking-names-and-rails?source=tweet\" data-url=\"https://seekingalpha.com/news/3361506-trade-worries-hit-trucking-names-and-rails\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361505\" data-ts=\"1528142058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FPRX\" target=\"_blank\">FPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361505-five-prime-pivots-on-bemarituzumab-to-first-line-setting-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Prime pivots on bemarituzumab to first-line setting; shares down 9%</a></h4><ul><li>Investors appear disappointed with Five Price Therapeutics' (<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a> <font color='red'>-9.1%</font>) decision to pursue <a href=\"https://seekingalpha.com/pr/17180820-five-prime-therapeutics-presents-bemarituzumab-trial-progress-poster-2018-asco-annual-meeting\" target=\"_blank\">approval </a>for FGFR tyrosine kinase inhibitor bemarituzumab in a first-line setting versus late-line use.</li><li>The Phase 3 portion of a Phase 1/3 clinical trial, FIGHT, assessing bemarituzumab plus mFOLFOX6 chemo compared to placebo plus mFOLFOX6 in patients with gastric cancer &#40;GC&#41; or gastroesophageal junction cancer &#40;GEJ&#41; whose tumors overexpress FGFR2b should launch in H2. The primary endpoint will be overall survival &#40;OS&#41;.</li><li>Phase 1 results in 21 GC/GEJ patients with high FGFR2b expression&nbsp;treated with bemarituzumab alone showed a overall response rate &#40;ORR&#41; of 19.0%, including four confirmed partial responders, and a disease control rate of 54.9%. Median duration of response was 15.4 weeks.</li><li>The company says first-line chemo prolongs survival by about six months compared to best supportive care, but median OS remains poor at 10-11 months and progression-free survival &#40;PFS&#41; at 5.0-5.6 months. Patients with FGFR2b overexpression, representing ~10% of GC/GEJ cases, have poor prognoses.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361505\" data-linked=\"Five Prime pivots on bemarituzumab to first-line setting; shares down 9%\" data-tweet=\"$FPRX - Five Prime pivots on bemarituzumab to first-line setting; shares down 9% https://seekingalpha.com/news/3361505-five-prime-pivots-on-bemarituzumab-to-first-line-setting-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3361505-five-prime-pivots-on-bemarituzumab-to-first-line-setting-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361502\" data-ts=\"1528141444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSNNF\" target=\"_blank\">SSNNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361502-samsung-admits-to-visit-from-chinese-regulators\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Samsung admits to visit from Chinese regulators</a></h4><ul><li>        Samsung (<a href='https://seekingalpha.com/symbol/SSNNF' title='Samsung Electronics Co., Ltd.'>OTC:SSNNF</a>, <a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>) is the latest company to <a href=\"https://www.reuters.com/article/us-samsung-elec-china/samsung-confirms-chinese-officials-visited-sales-offices-idUSKCN1J02DI\" target=\"_blank\">confirm</a> that its sales offices received a visit from China&rsquo;s State Administration for Market Regulation last week. &nbsp;</li><li>        A Samsung spokesman tells Reuters the company is cooperating with authorities but didn&rsquo;t provide more details about the visit.</li><li>               The visit to Samsung and SK Hynix was reported by the Wall Street Journal earlier today while Micron announced its visit last Friday.&nbsp;</li><li>               Samsung, SK Hynix, and Micron are the largest DRAM suppliers and DRAM prices are high. Analysts think China is trying to protect its smartphone and PC markets from rising DRAM costs as those products have tighter margins than in other countries.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361273-china-launches-foreign-chipmaker-probe\" target=\"_blank\">China launches foreign chipmaker probe</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361502\" data-linked=\"Samsung admits to visit from Chinese regulators\" data-tweet=\"$SSNNF $SSNNF $SSNLF - Samsung admits to visit from Chinese regulators https://seekingalpha.com/news/3361502-samsung-admits-to-visit-from-chinese-regulators?source=tweet\" data-url=\"https://seekingalpha.com/news/3361502-samsung-admits-to-visit-from-chinese-regulators\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361500\" data-ts=\"1528140429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNOM\" target=\"_blank\">VNOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361500-viper-energy-partnersminus-6-following-stifel-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viper Energy Partners -6% following Stifel downgrade</a></h4><ul>     <li>Viper Energy Partners (<a href='https://seekingalpha.com/symbol/VNOM' title='Viper Energy Partners LP'>VNOM</a> <font color='red'>-5.8%</font>) plunges after Stifel <a href=\"https://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Viper+Energy+%28VNOM%29+to+Hold/14265805.html\" target=\"_blank\">downgrades</a> shares to Hold from Buy with a $32 price target, trimmed from $33, believing VNOM should create significant long-term value but seeing uncertainty for the next 12 months with widening basis differentials potentially weighing on units.</li><li>Stifel continues to expect distributions to trend modestly higher through 2018 followed by a modest decline in H1 2019 before growth resumes into H2.</li><li>The firm also notes VNOM short interest is trending higher with units offering a mostly pure play vehicle for investors with a bearish view on Permian basis or near-term growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361500\" data-linked=\"Viper Energy Partners -6% following Stifel downgrade\" data-tweet=\"$VNOM - Viper Energy Partners -6% following Stifel downgrade https://seekingalpha.com/news/3361500-viper-energy-partnersminus-6-following-stifel-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3361500-viper-energy-partnersminus-6-following-stifel-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361496\" data-ts=\"1528139790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBE\" target=\"_blank\">OBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361496-obsidian-energy-to-spend-additional-50m-for-cardium-development\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Obsidian Energy to spend additional $50M for Cardium development</a></h4><ul>     <li>Obsidian Energy (<a href='https://seekingalpha.com/symbol/OBE' title='Obsidian Energy Ltd.'>OBE</a> <font color='red'>-3.6%</font>) is lower after saying it plans to raise its FY 2018 capital budget by $50M to <a href=\"https://seekingalpha.com/pr/17181018-obsidian-energy-announces-strategic-update-additional-50-million-cardium-development\" target=\"_blank\">fund 13 more wells</a> in its Willesden Green property in Alberta during H2, after production from its Cardium drilling program in the play exceeded expectations.</li>     <li>OBE expects to add ~2,300 boe/day in FY 2019 from  the new wells, with monthly production reaching 3,500 boe/early next year.</li>     <li>OBE says the incremental wells will be brought on production with an estimated two-month capital efficiency of $20K/boe per day, averaging more than 80% rate of return at strip prices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361496\" data-linked=\"Obsidian Energy to spend additional $50M for Cardium development\" data-tweet=\"$OBE - Obsidian Energy to spend additional $50M for Cardium development https://seekingalpha.com/news/3361496-obsidian-energy-to-spend-additional-50m-for-cardium-development?source=tweet\" data-url=\"https://seekingalpha.com/news/3361496-obsidian-energy-to-spend-additional-50m-for-cardium-development\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361490\" data-ts=\"1528138514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDR\" target=\"_blank\">BDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361490-technology-top-5-gainers-losers-of-2_55-pm-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (06/04/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/BDR' title='Blonder Tongue Laboratories, Inc'>BDR</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/SOGO' title='Sogou'>SOGO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/PS' title='Pluralsight, Inc.'>PS</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/GIGM' title='GigaMedia Limited'>GIGM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ZUO' title='Zuora, Inc.'>ZUO</a> <font color='green'>+8%</font>.</li>     <li><strong>Losers</strong>: <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/RFIL' title='RF Industries, Ltd.'>RFIL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-11%</font>.</li> &nbsp;     &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3361490\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (06/04/2018)\" data-tweet=\"$BDR $BDR $SOGO - Technology - Top 5 Gainers / Losers as of 2.55 PM (06/04/2018) https://seekingalpha.com/news/3361490-technology-top-5-gainers-losers-of-2_55-pm-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361490-technology-top-5-gainers-losers-of-2_55-pm-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361489\" data-ts=\"1528138402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPE\" target=\"_blank\">CPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361489-callon-petroleum-not-affected-el-paso-force-majeure-event-rbc-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Callon Petroleum not affected by El Paso force majeure event, RBC says</a></h4><ul>     <li>Callon Petroleum (<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Co.'>CPE</a> <font color='red'>-7.3%</font>) plunges in reaction to a <a href=\"https://www.streetinsider.com/Analyst+Comments/Callon+Petroleum+%28CPE%29+Defended+at+RBC%2C+Says+Remainder+of+El+Paso+Not+Impacted/14268227.html\" target=\"_blank\">force majeure event</a> on the El Paso gas system in the Permian, which prompted a note from RBC&nbsp;Capital analyst Brad&nbsp;Heffern suggesting  that CPE likely would be affected.</li><li>But the analyst reportedly has since said CPE does not ship any volumes on the affected line and that its volumes on the rest of the El Paso system were not affected.</li><li>RBC reiterates an Outperform rating and $16 price target on CPE shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361489\" data-linked=\"Callon Petroleum not affected by El Paso force majeure event, RBC says\" data-tweet=\"$CPE - Callon Petroleum not affected by El Paso force majeure event, RBC says https://seekingalpha.com/news/3361489-callon-petroleum-not-affected-el-paso-force-majeure-event-rbc-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3361489-callon-petroleum-not-affected-el-paso-force-majeure-event-rbc-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361487\" data-ts=\"1528138246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361487-wynn-resorts-lower-after-deutsche-bank-caution\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wynn Resorts lower after Deutsche Bank caution</a></h4><ul> <li>Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) is<font color='red'> down 5.94%</font> after Deutsche Bank cuts estimates on the casino stock.</li> <li>The investment firm warns that the World Cup soccer tournament will be a major drag on casino traffic and sees more spillover from the weak VIP revenue print from Macau for May.</li> <li>DB is still bullish on Wynn for the long term.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361060-macau-names-lower-may-revenue-update\" target=\"_blank\">Macau names lower after May revenue update</a> (June 1)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3361487\" data-linked=\"Wynn Resorts lower after Deutsche Bank caution\" data-tweet=\"$WYNN - Wynn Resorts lower after Deutsche Bank caution https://seekingalpha.com/news/3361487-wynn-resorts-lower-after-deutsche-bank-caution?source=tweet\" data-url=\"https://seekingalpha.com/news/3361487-wynn-resorts-lower-after-deutsche-bank-caution\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361486\" data-ts=\"1528138175\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SC\" target=\"_blank\">SC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361486-santander-consumer-usaplus-3-analyst-values-chrysler-capital-1_2b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Santander Consumer USA +3% as analyst values Chrysler Capital at $1.2B</a></h4><ul><li>Santander Consumer US (NYSE:<a href='https://seekingalpha.com/symbol/SC' title='Santander Consumer USA Holdings Inc'>SC</a>)&nbsp;<font color='green'>+3%</font>&nbsp;after Susquehanna analyst Jack Micenko says in a note that the financial firm's Chrysler Capital unit is valued at about $1.2B, assuming a 6x earnings multiple.</li><li>SC's \"scarcity value\" may be worth even more, Bloomberg reports, citing Micenko's note to investors.</li><li>Fiat Chrysler (NYSE:<a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a>) announced on June 1 that it would form a U.S. finance arm and would consider buying Chrysler Capital from SC. That would be the best fit for FCAU to retain flow agreements as it related to future subprime loan production at the new captive, Micenko says.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361072-fiat-chrysler-bring-u-s-financial-services-house\" target=\"_blank\">Fiat Chrysler to bring U.S. financial services  in-house</a> (June 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361486\" data-linked=\"Santander Consumer USA +3% as analyst values Chrysler Capital at $1.2B\" data-tweet=\"$SC $SC $FCAU - Santander Consumer USA +3% as analyst values Chrysler Capital at $1.2B https://seekingalpha.com/news/3361486-santander-consumer-usaplus-3-analyst-values-chrysler-capital-1_2b?source=tweet\" data-url=\"https://seekingalpha.com/news/3361486-santander-consumer-usaplus-3-analyst-values-chrysler-capital-1_2b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361485\" data-ts=\"1528137580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361485-fitbit-versa-ships-one-millionth-device-in-seven-weeks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit Versa ships one millionth device in seven weeks</a></h4><ul>   <li>Fitbit (<a href=\"http://seekingalpha.com/symbol/FIT\" target=\"_blank\">FIT</a> <font color='green'>+3.4%</font>) has hit a milestone with its Versa device, having <a href=\"https://seekingalpha.com/pr/17181618-fitbit-ships-one-million-fitbit-versa-devices-two-million-use-female-health-tracking-within\" target=\"_blank\">shipped more than 1M</a> since the April 16 general availability.</li>    <li>That makes it the fastest selling product in Fitbit's history.</li>    <li>Meanwhile, a female health tracking feature that the company added last month picked up more than a million users in its first two weeks, and more than 2.4M have started using it within a month as it added Android support.</li>    <li>The company adds that it stills sees growth in apps and clock faces made for its Fitbit OS -- more than 900 have been built from a community that includes more than 18,000 developers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361485\" data-linked=\"Fitbit Versa ships one millionth device in seven weeks\" data-tweet=\"$FIT - Fitbit Versa ships one millionth device in seven weeks https://seekingalpha.com/news/3361485-fitbit-versa-ships-one-millionth-device-in-seven-weeks?source=tweet\" data-url=\"https://seekingalpha.com/news/3361485-fitbit-versa-ships-one-millionth-device-in-seven-weeks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361484\" data-ts=\"1528137529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVE\" target=\"_blank\">CVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361484-reuters-conocophillips-preparing-to-sell-stake-in-cenovus-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: ConocoPhillips preparing to sell stake in Cenovus Energy</a></h4><ul>     <li>Cenovus Energy (<a href='https://seekingalpha.com/symbol/CVE' title='Cenovus Energy, Inc.'>CVE</a> <font color='red'>-7.4%</font>) sinks following a Reuters report that ConocoPhillips (<a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color='red'>-0.5%</font>) is <a href=\"https://www.reuters.com/article/us-conocophillips-cenovus-energy-exclusi/exclusive-conocophillips-prepares-to-sell-stake-in-canadas-cenovus-sources-idUSKCN1J02IE\" target=\"_blank\">preparing to dispose of its ~C$2.7B stake</a> in the company.</li><li>COP has held talks with investment banks about appointing advisors to  the sale and could offer the shares to institutional investors as early  as this month, according to the report.</li><li>If COP does not complete the sale in June or early July, it  then would likely wait until September when institutional investors will  have returned from their summer vacations, the report says.</li><li>CVE last year acquired oil sands and natural gas assets from COP for C$14.1B in cash and 208M CVE shares, making COP the company's largest shareholder.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361484\" data-linked=\"Reuters: ConocoPhillips preparing to sell stake in Cenovus Energy\" data-tweet=\"$CVE $CVE $COP - Reuters: ConocoPhillips preparing to sell stake in Cenovus Energy https://seekingalpha.com/news/3361484-reuters-conocophillips-preparing-to-sell-stake-in-cenovus-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3361484-reuters-conocophillips-preparing-to-sell-stake-in-cenovus-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361482\" data-ts=\"1528136711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361482-viacom-veteran-zarghami-leaving-helm-of-nickelodeon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom veteran Zarghami leaving helm of Nickelodeon</a></h4><ul>   <li>A transition's under way at Nickelodeon, Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+2%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='green'>+0.6%</font>) says, with president Cyma Zarghami <a href=\"http://www.viacom.com/news/Pages/newsdetails.aspx?RID=1069224\" target=\"_blank\">exiting her post</a> after spending more than 30 years at the network.</li>    <li>Sarah Levy, COO of Viacom Media Networks, will take over Nick while the company conducts a search to find a new president.</li>    <li>The interim team will focus on launching Nickelodeon's biggest-ever content pipeline, with more than 800 new episodes on the way.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361482\" data-linked=\"Viacom veteran Zarghami leaving helm of Nickelodeon\" data-tweet=\"$VIA $VIA $VIAB - Viacom veteran Zarghami leaving helm of Nickelodeon https://seekingalpha.com/news/3361482-viacom-veteran-zarghami-leaving-helm-of-nickelodeon?source=tweet\" data-url=\"https://seekingalpha.com/news/3361482-viacom-veteran-zarghami-leaving-helm-of-nickelodeon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361480\" data-ts=\"1528136120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GHDX\" target=\"_blank\">GHDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361480-study-confirms-value-proposition-of-genomic-healths-oncotype-dx-shares-up-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Study confirms value proposition of Genomic Health&#39;s Oncotype DX; shares up 18%</a></h4><ul><li>Data from the TAILORx study, assessing the ability of Genomic Health's (<a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='green'>+18.3%</font>) <a href=\"http://www.mybreastcancertreatment.org/en-US/LearnAboutOncotypeDX?gclid=Cj0KCQjwxtPYBRD6ARIsAKs1XJ6nrah-tUBQUVcaMtIIhm_b--UEWxYp6UaFK9s3_xTlzArnPgWcw70aAskGEALw_wcB\" target=\"_blank\">Oncotype DX Breast Recurrence Score test </a>to predict which breast cancer patients could be treated with endocrine therapy alone,&nbsp;<a href=\"https://seekingalpha.com/pr/17180814-landmark-tailorx-results-published-today-new-england-journal-medicine-demonstrate-oncotype-dx\" target=\"_blank\">confirmed its value</a> in guiding physicians to the most appropriate therapy for these patients. The results were presented as ASCO and will be published today in <em>The New England Journal of Medicine.&nbsp;</em></li><li>Oncotype DX scores of 0-25 identified 70% of early-stage breast cancer patients with HR+/HER2-, node-negative breast cancer who would receive no benefit from chemotherapy and could be effectively treated with endocrine therapy alone. Conversely, it identified the 30% who could benefit from chemo via scores of 26-100.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361480\" data-linked=\"Study confirms value proposition of Genomic Health&#39;s Oncotype DX; shares up 18%\" data-tweet=\"$GHDX - Study confirms value proposition of Genomic Health&#39;s Oncotype DX; shares up 18% https://seekingalpha.com/news/3361480-study-confirms-value-proposition-of-genomic-healths-oncotype-dx-shares-up-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3361480-study-confirms-value-proposition-of-genomic-healths-oncotype-dx-shares-up-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361481\" data-ts=\"1528136113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLNG\" target=\"_blank\">GLNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361481-golar-lngplus-4-hilli-episeyo-starts-full-commercial-operation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golar LNG +4% as Hilli Episeyo starts full commercial operation</a></h4><ul>     <li>Golar LNG&nbsp;(<a href='https://seekingalpha.com/symbol/GLNG' title='Golar LNG Limited'>GLNG</a> <font color='green'>+3.9%</font>) and Golar LNG&nbsp;Partners (<a href='https://seekingalpha.com/symbol/GMLP' title='Golar LNG Partners LP'>GMLP</a> <font color='green'>+5.4%</font>) are higher after announcing the <a href=\"https://seekingalpha.com/pr/17181657-golar-lng-flng-hilli-episeyo-customer-acceptance\" target=\"_blank\">start of commercial operations</a> at the Hilli Episeyo floating LNG plant offshore Cameroon, marking completion of the first-ever conversion of an LNG carrier into a production facility.</li><li>Golar says the Hilli Episeyo generated 7.5K cm/day of LNG during a 16-day test period and likely will add $164M in yearly EBITDA as well as $45M in additional operating cash flow for the company, based on its commercial tolling rate.</li><li>The launch of commercial operations also allows Golar to draw on a $960M lease financing facility that will replace the existing loan package.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361481\" data-linked=\"Golar LNG +4% as Hilli Episeyo starts full commercial operation\" data-tweet=\"$GLNG $GLNG $GMLP - Golar LNG +4% as Hilli Episeyo starts full commercial operation https://seekingalpha.com/news/3361481-golar-lngplus-4-hilli-episeyo-starts-full-commercial-operation?source=tweet\" data-url=\"https://seekingalpha.com/news/3361481-golar-lngplus-4-hilli-episeyo-starts-full-commercial-operation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361475\" data-ts=\"1528135232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SID\" target=\"_blank\">SID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361475-energy-materials-top-5-gainers-losers-of-2-00-pm-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SID' title='Companhia Siderurgica Nacional'>SID</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/OCIP' title='OCI Partners, LP'>OCIP</a> <font color='green'>+10%</font>. PBR-A <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/NXE' title='Nexgen Energy Ltd.'>NXE</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ENSV' title='Enservco Corp.'>ENSV</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SM' title='SM Energy Company'>SM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361475\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/04/2018)\" data-tweet=\"$SID $SID $CHNR - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/04/2018) https://seekingalpha.com/news/3361475-energy-materials-top-5-gainers-losers-of-2-00-pm-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361475-energy-materials-top-5-gainers-losers-of-2-00-pm-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361474\" data-ts=\"1528135189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRSN\" target=\"_blank\">MRSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361474-investors-underwhelmed-mersanas-early-stage-data-on-lead-candidate-xmtminus-1522-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors underwhelmed with Mersana&#39;s early-stage data on lead candidate XMT-1522; shares down 18%</a></h4><ul><li>Thinly traded micro cap Mersana Therapeutics (<a href='https://seekingalpha.com/symbol/MRSN' title='Mersana Therapeutics'>MRSN</a> <font color='red'>-17.7%</font>) slumps on modestly higher volume in apparent reaction to its <a href=\"https://seekingalpha.com/pr/17181600-mersana-presents-interim-dose-escalation-data-xmtminus-1522-select-cancers-asco-2018\" target=\"_blank\">announcement </a>of updated data from a Phase 1 clinical trial evaluating lead antibody-drug conjugate &#40;ADC&#41; XMT-1522 in HER2-positive breast, non-small lung and gastric cancers. The results were presented at ASCO in Chicago.</li><li>Dose-limiting toxicity assessments have been completed across six dose levels (seventh is in process) but the maximum tolerated dose has not been reached. Advancement into Phase 2 development is on hold until the recommended dose is determined.</li><li>Of the 13 patients receiving 16 mg/m<sup>2</sup>&nbsp;or greater, one experienced a partial response while 11 had stable cancer, implying a disease control rate of 75%.</li><li>The company will host a conference call and webcast today at 6:30 pm CT to review the data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361474\" data-linked=\"Investors underwhelmed with Mersana&#39;s early-stage data on lead candidate XMT-1522; shares down 18%\" data-tweet=\"$MRSN - Investors underwhelmed with Mersana&#39;s early-stage data on lead candidate XMT-1522; shares down 18% https://seekingalpha.com/news/3361474-investors-underwhelmed-mersanas-early-stage-data-on-lead-candidate-xmtminus-1522-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3361474-investors-underwhelmed-mersanas-early-stage-data-on-lead-candidate-xmtminus-1522-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361504\" data-ts=\"1528134551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCIP\" target=\"_blank\">OCIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361504-oci-offers-to-buy-remaining-oci-partners-units-for-11-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OCI offers to buy remaining OCI Partners units for $11/unit</a></h4><ul>     <li>OCI Partners (<a href='https://seekingalpha.com/symbol/OCIP' title='OCI Partners, LP'>OCIP</a> <font color='green'>+9.5%</font>) says general partner owned OCI N.V. launched an unsolicited tender offer to <a href=\"https://seekingalpha.com/pr/17181019-oci-partners-lps-board-directors-review-unsolicited-tender-offer-oci-n-v\" target=\"_blank\">acquire all remaining common units</a> representing limited partner interests in OCIP for $11/unit in cash, a 10% premium over OCIP's closing price on June 1.</li><li>OCI already owns 88.25% of OCIP's issued and outstanding common units.</li><li>OCIP owns and operates an integrated methanol and ammonia production facility on the Texas Gulf Coast with a methanol production design capacity of 912.5K metric tons/year and an ammonia production design capacity of  331K metric tons/year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361504\" data-linked=\"OCI offers to buy remaining OCI Partners units for $11/unit\" data-tweet=\"$OCIP - OCI offers to buy remaining OCI Partners units for $11/unit https://seekingalpha.com/news/3361504-oci-offers-to-buy-remaining-oci-partners-units-for-11-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3361504-oci-offers-to-buy-remaining-oci-partners-units-for-11-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361472\" data-ts=\"1528133477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APEN\" target=\"_blank\">APEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361472-apollo-endosurgery-down-8-on-uptick-in-malfunction-rate-of-intragastric-balloon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apollo Endosurgery down 8% on uptick in malfunction rate of intragastric balloon</a></h4><ul><li>Thinly traded micro cap Apollo Endosurgery (<a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='red'>-8.1%</font>) slips on more than double normal volume, albeit on turnover of only 43K shares, in apparent response to its <a href=\"https://seekingalpha.com/pr/17181974-apollo-endosurgery-announces-fda-approval-revised-labeling-orbera-intragastric-balloon-system\" target=\"_blank\">announcement </a>of labeling updates for intragastric balloon system ORBERA, used to control food intake (thereby promoting weight loss) in obese patients.</li><li>The new information, revised Directions for Use for doctors and patients and physician training information, also includes updated mortality and complication rates. All are comparable from a year ago except the rate of <a href=\"http://www.latimes.com/science/sciencenow/la-sci-sn-gastric-balloon-20170810-story.html\" target=\"_blank\">spontaneous hyperinflation</a>, a situation where the saline-filled balloon overinflates with air or liquid requiring early removal. The rate as of March 31 was 0.07%, up 75% from 0.04% last year.</li><li>ReShape Lifesciences (<a href='https://seekingalpha.com/symbol/RSLS' title='ReShape Lifesciences Inc.'>OTC:RSLS</a> <font color='red'>-8.3%</font>), maker of the <a href=\"https://www.reshapelifesciences.com/reshape-gastric-balloon/\" target=\"_blank\">ReShape gastric balloon</a>, is down in sympathy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361472\" data-linked=\"Apollo Endosurgery down 8% on uptick in malfunction rate of intragastric balloon\" data-tweet=\"$APEN $APEN $RSLS - Apollo Endosurgery down 8% on uptick in malfunction rate of intragastric balloon https://seekingalpha.com/news/3361472-apollo-endosurgery-down-8-on-uptick-in-malfunction-rate-of-intragastric-balloon?source=tweet\" data-url=\"https://seekingalpha.com/news/3361472-apollo-endosurgery-down-8-on-uptick-in-malfunction-rate-of-intragastric-balloon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361471\" data-ts=\"1528132684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLTH\" target=\"_blank\">DLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361471-duluth-holdings-volatile-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Duluth Holdings volatile ahead of earnings</a></h4><ul> <li>Shares of Duluth Holdings (<a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='green'>+3.1%</font>) are volatile ahead of the retailer's Q1 earnings report due out tomorrow before the opening bell.</li> <li>Things could get even more turbulent tomorrow as Bloomberg reports that short interest on Duluth now represents 57% of the stock's float.</li> <li>Duluth reports just as consumer spending in retail appears to have picked up after a slow start to the warmer weather season.</li> <li>Analysts expect Duluth to report a $0.05 EPS loss for the quarter off of revenie fof $101M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361471\" data-linked=\"Duluth Holdings volatile ahead of earnings\" data-tweet=\"$DLTH - Duluth Holdings volatile ahead of earnings https://seekingalpha.com/news/3361471-duluth-holdings-volatile-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3361471-duluth-holdings-volatile-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361467\" data-ts=\"1528131885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361467-deciphera-pharma-up-33-on-positive-dccminus-2618-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deciphera Pharma up 33% on positive DCC-2618 data</a></h4><ul><li>Thinly traded Deciphera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> <font color='green'>+33.2%</font>) is up on almost an 8x surge in volume, albeit on turnover of less than 1M shares, following its <a href=\"https://seekingalpha.com/pr/17180781-deciphera-pharmaceuticals-reports-updated-interim-phase-1-clinical-study-results-dccminus\" target=\"_blank\">announcement </a>of positive data from a Phase 1 clinical trial assessing lead candidate DCC-2618 in patients with gastrointestinal stromal tumors &#40;GIST&#41;. The results were presented at ASCO in Chicago.</li><li>When administered in a second-line setting, the overall response rate &#40;ORR&#41; was 24% and the disease control rate &#40;DCR&#41; was 79% (n=25).</li><li>In a third-line setting, ORR and DCR were 24% and 82%, respectively (n=29).</li><li>In a fourth-line or greater setting, ORR and DCR were 9% and 64%, respectively (n=91).</li><li>The company says the 24% ORR and 80% three-month DCR in combined second- and third-line patients (at doses at least 100 mg/day) exceed previously published registrational trial data for second-line sunitinib (7%/60%)(Pfizer's Sutent) and third-line regorafenib (4.5%/53%)(Bayer's Stivarga).</li><li>A Phase 3 study, INTRIGUE, in second-line GIST will launch this year. The primary endpoint will be median progression-free survival &#40;PFS&#41;.</li><li><a href=\"https://www.deciphera.com/pipeline/dcc-2618/\" target=\"_blank\">DCC-2618</a>&nbsp;inhibits certain kinase enzymes (KIT and PDDGa) that play a key role in the proliferation and survival of certain cancers, including brain cancer, GIST and systemic mastocytosis.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a> <font color='red'>-0.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361467\" data-linked=\"Deciphera Pharma up 33% on positive DCC-2618 data\" data-tweet=\"$DCPH $DCPH $PFE - Deciphera Pharma up 33% on positive DCC-2618 data https://seekingalpha.com/news/3361467-deciphera-pharma-up-33-on-positive-dccminus-2618-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3361467-deciphera-pharma-up-33-on-positive-dccminus-2618-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361464\" data-ts=\"1528131663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDC\" target=\"_blank\">CLDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361464-financials-top-5-gainers-losers-of-1-00-pm-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (06/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/FFNW' title='First Financial Northwest, Inc.'>FFNW</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TCI' title='Transcontinental Realty Investors Inc.'>TCI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CMFN' title='CM Finance'>CMFN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Ltd'>DNJR</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361464\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (06/04/2018)\" data-tweet=\"$CLDC $CLDC $FFNW - Financials - Top 5 Gainers / Losers as of 1:00 PM (06/04/2018) https://seekingalpha.com/news/3361464-financials-top-5-gainers-losers-of-1-00-pm-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361464-financials-top-5-gainers-losers-of-1-00-pm-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361426\" data-ts=\"1528131413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OESX\" target=\"_blank\">OESX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361426-orion-energy-systemss-up-2-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orion Energy Systems&#39;s up 2% post Q4 results</a></h4><ul><li>Orion Energy Systems (<a href='https://seekingalpha.com/symbol/OESX' title='Orion Energy Systems, Inc'>OESX</a> <font color='green'>+2.9%</font>) reported Q4 revenue of $15.06M (-1.5% Y/Y). Segment revenues: LED lighting product $13.71M (-1.65% Y/Y) and service revenue $1.34M (-0.52% Y/Y).</li><li>Q4 Margins: Gross&nbsp;<font color='green'>improved by 1,545 bps</font>&nbsp;to 21.42%, operating margin recovered by 3,688 bps to -10.5% and EBITDA&nbsp;<font color='green'>recovered by 3,820 bps</font>&nbsp;to -5.74%.</li><li>Q4 Expenses: G&amp;A declined by 52% Y/Y to $1.79M, sales and marketing declined by 28% Y/Y to $2.64M and R&amp;D declined by 24.5% Y/Y to $0.38M.</li><li>&ldquo;FY 2018 proved to be a transitional year in which we focused on revenue generating initiatives while also right-sizing our organization to reflect the current size of the business. While we had expected to see the benefit of our national account focus, agent driven distribution model initiative, and reinvigoration of our Energy Service Company and reseller relationships during FY 2018, we are now starting to see these efforts materialize in discussions that should provide significant business opportunities beginning in the second and third quarters of fiscal 2019&rdquo;, commented Mike Altschaefl, CEO.</li><li>FY19 Outlook: Revenue growth of 10% Y/Y; achieve 30% gross margin and break-even EBITDA by 2Q19.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361322-orion-energy-systems-beats-0_02-misses-revenue\" target=\"_blank\">Orion Energy Systems beats by $0.02, misses on revenue</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361426\" data-linked=\"Orion Energy Systems&#39;s up 2% post Q4 results\" data-tweet=\"$OESX - Orion Energy Systems&#39;s up 2% post Q4 results https://seekingalpha.com/news/3361426-orion-energy-systemss-up-2-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3361426-orion-energy-systemss-up-2-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361460\" data-ts=\"1528131234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361460-apple-kicks-off-wwdc-live-updates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple kicks off WWDC (live updates)</a></h4><ul><li>Apple's (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) annual Worldwide Developers Conference starts today with the keynote scheduled to begin at 1 PM Eastern.</li><li>Watch the event live <a href=\"https://www.apple.com/apple-events/june-2018/\" target=\"_blank\">here</a>.</li><li><strong>Update:</strong>&nbsp;                  CEO Tim Cook says there are now 20M Apple developers worldwide.</li><li>The App Store turns 10 next month and it now welcomes over 500M weekly visitors.</li><li>This week, the money that developers have earned from the App Store will top $100B dollars for the first time.&nbsp; (Apple gets around 30% of the cut or 15% from developers who get users into long-term subscriptions.)</li><li><strong>Update:</strong> IOS: Software Engineering SVP Craig Federighi announces iOS 12 and says that 81% of the current iOS install base is using iOS 11 right now.</li><li>IOS 12 will be available or every device that supports iOS 12 so older devices won&rsquo;t get left in the cold.</li><li>In iOS 12, apps launch 40% faster, keyboard launches 50% faster, and camera launches 70% faster on older devices.</li><li><strong>Update:</strong> ARKit: Apple worked with Pixar to make the new file format for AR: USDZ, which is described as &ldquo;something like AR Quick Look.&rdquo; The format allows for a WYSIWYG experience in AR.</li><li>Companies supporting the new file format include Adobe (with an appearance on the WWDC stage), Autodesk, Sketchfab, and Quixel. It also works in News and on the web.</li><li>New AR measurement tool called Measure introduced. The app has a camera view and tabs for measuring and using it as a level.</li><li>ARKit 2 gets improved facial tracking, realistic rendering, 3D object detection, and the expected shared experiences feature that lets users have the same experience on multiple iPhones.</li><li><strong>Update:&nbsp;</strong>Photos: Search is getting improved with better photo recognition. Photos will index events by time and place. A &ldquo;For You&rdquo; tab will include featured photo suggestions and a Sharing section that suggests where and how to share certain pictures.</li><li><strong>Update:&nbsp;</strong> Siri: New feature/app Shortcuts lets any app &ldquo;expose quick actions to Siri.&rdquo; Users can record a custom phrase with the Add to Siri function. For example, &ldquo;travel plans&rdquo; could launch the Kayak app and trip reservation details. Siri Suggestions can be added to the lockscreen for things done on a daily basis, like checking traffic or ordering coffee.</li><li><strong>Update:&nbsp;</strong>                  App news: Stocks app gets a News element with curated business news stories and iPad support. Voice Memos getting a rebuild and iPad support. Apple Books gets new name, new design, and a &ldquo;reading now&rdquo; feature as a progress reminder.</li><li>Managing device use: Do Not Disturb is easier to activate and will include timers and new controls for bedtime and in the morning. IOS notifications will be grouped on the lockscreen, it will be easier to customize notifications, and Siri can suggest you turn off notifications for unused apps.</li><li>And the expected Screen Time app that shows how much time the user spends staring at the phone screen/certain apps, which includes a weekly activity summary. Parents can get the summary from their child&rsquo;s phone and set allowances to limit time or access to certain apps.</li><li><strong>Update:</strong>&nbsp;                  FaceTime gets group chats that can support up to 32 people. This can launch the traditional way or through Messages, which will now have a FaceTime launch button.</li><li><strong>Update:&nbsp;</strong>                  WatchOS 5 includes the ability to challenge friends and improves the workout modes for Yoga and Hiking. WatchOS 5 can now detect when a workout starts and stops. &nbsp;Watch gets Walkie Talkie to communicate through cellular or Wi-Fi. Webkit is coming to be able to see the content from a link. The Podcast app is also coming to the Watch.</li><li><strong>Update</strong>: Apple TV 4K gets Dolby (NYSE:<a href='https://seekingalpha.com/symbol/DLB' title='Dolby Laboratories, Inc.'>DLB</a>) Atmos support. Atmos 4K content is available from Amazon and Netflix but Apple says iTunes will have the most Atmos 4K content.</li><li><strong>Update:</strong>&nbsp;                  Mac OS Mojave: &nbsp;The OS gets Dark Mode that helps pictures and documents (or Xcode) stand out more. The UI goes dark, as do the browser, browser content, and the desktop. Another desktop feature: Stacks for auto-organizing cluttered desktops. Finder gets a Gallery view, the ability to edit photos, and the ability to select multiple files and do the same thing to them all like assembling the files into a PDF.</li><li>Screenshots in Mojave looks like the improved version on iOS. The screenshot puts an editable image in the corner of the screen.</li><li>Continuity Camera: Users can take a picture on an iPhone and it pops up directly on the Mac. This feature also works for scanning documents.</li><li>Mac apps: News, Stocks, Voice Memos, and Home (for smart home control) are coming to the Mac.</li><li><strong>Update:</strong>&nbsp;                  Mac App Store gets a redesign and some holdout apps like Microsoft&rsquo;s Office 365 and Adobe&rsquo;s Lightroom.</li><li>               Privacy in Mac: Apple will offer more notifications when apps want access to the camera, microphone, mail, or messages. Mojave will add Safari changes to make it harder to track a user based on cookies or other system data.&nbsp;</li><li>WWDC keynote has come to a close. Apple share are&nbsp;<font color='green'>up 1%</font>&nbsp;to $192.07.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3361460\" data-linked=\"Apple kicks off WWDC (live updates)\" data-tweet=\"$AAPL $AAPL $DLB - Apple kicks off WWDC (live updates) https://seekingalpha.com/news/3361460-apple-kicks-off-wwdc-live-updates?source=tweet\" data-url=\"https://seekingalpha.com/news/3361460-apple-kicks-off-wwdc-live-updates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361456\" data-ts=\"1528130775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABAC-OLD\" target=\"_blank\">ABAC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361456-midday-gainers-losers-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (06/04/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/BDR' title='Blonder Tongue Laboratories, Inc'>BDR</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/GLMD' title='Galmed Pharmaceuticals Ltd.'>GLMD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SID' title='Companhia Siderurgica Nacional'>SID</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a> <font color='green'>+13%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='red'>-39%</font>. <a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/NES' title='Nuverra Environmental Solutions, Inc.'>NES</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/OCX' title='OncoCyte Corporation'>OCX</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/MRSN' title='Mersana Therapeutics'>MRSN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/TCI' title='Transcontinental Realty Investors Inc.'>TCI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a> <font color='red'>-15%</font>.</li>     &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3361456\" data-linked=\"Midday Gainers / Losers (06/04/2018)\" data-tweet=\"$ABAC-OLD $ABAC-OLD $DCPH - Midday Gainers / Losers (06/04/2018) https://seekingalpha.com/news/3361456-midday-gainers-losers-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361456-midday-gainers-losers-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361453\" data-ts=\"1528130361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWBO\" target=\"_blank\">NWBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361453-northwest-bio-down-12-after-underwhelming-asco-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northwest Bio down 12% after underwhelming ASCO presentation</a></h4><ul><li>Micro cap Northwest Biotherapeutics (<a href='https://seekingalpha.com/symbol/NWBO' title='Northwest Biotherapeutics, Inc.'>OTCQB:NWBO</a> <font color='red'>-12.2%</font>) slumps on more than double normal volume following its <a href=\"https://seekingalpha.com/pr/17179158-nw-bio-discuss-interim-phase-3-trial-data-industry-theater-session-asco\" target=\"_blank\">presentation </a>of <a href=\"https://www.nwbio.com/dcvax-personalized-dendritic-cell-vaccines/\" target=\"_blank\">preliminary data</a> from a late-stage study of DCVax-L in brain cancer as ASCO yesterday.</li><li>Results were based on blended data. The trial remains blinded so placebo data are included with treatment data so there is no way to ascertain the treatment effect until the study is unblinded.</li><li>Patient testimonials followed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361453\" data-linked=\"Northwest Bio down 12% after underwhelming ASCO presentation\" data-tweet=\"$NWBO - Northwest Bio down 12% after underwhelming ASCO presentation https://seekingalpha.com/news/3361453-northwest-bio-down-12-after-underwhelming-asco-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3361453-northwest-bio-down-12-after-underwhelming-asco-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361446\" data-ts=\"1528129357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IOVA\" target=\"_blank\">IOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361446-iovance-bio-in-green-on-encouraging-report-on-til-in-breast-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iovance Bio in the green on encouraging report on TIL in breast cancer</a></h4><ul><li>Iovance Biotherapeutics (<a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a> <font color='green'>+0.3%</font>) perks up on double normal volume on the heels of a Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2018-06-04/billions-of-fighting-cells-clear-woman-s-breast-cancer-in-study\" target=\"_blank\">report </a>of the successful use of tumor infiltrating lymphocytes (TILs) to eradicate breast cancer in a patient who had failed seven rounds of chemo and hormonal therapy.</li><li>The company develops TIL therapies. It is currently conducting three mid-stage studies assessing the approach in metastatic melanoma (C-144-01), head and neck cancer (C-145-03) and cervical cancer (C-145-04).</li></ul><div class=\"tiny-share-widget\" data-id=\"3361446\" data-linked=\"Iovance Bio in the green on encouraging report on TIL in breast cancer\" data-tweet=\"$IOVA - Iovance Bio in the green on encouraging report on TIL in breast cancer https://seekingalpha.com/news/3361446-iovance-bio-in-green-on-encouraging-report-on-til-in-breast-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3361446-iovance-bio-in-green-on-encouraging-report-on-til-in-breast-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361444\" data-ts=\"1528129221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JKS\" target=\"_blank\">JKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361444-several-solar-stocks-cut-roth-on-worse-expected-new-china-policy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Several solar stocks cut at Roth on &#39;worse than expected&#39; new China policy</a></h4><ul>     <li>JinkoSolar (<a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-11.1%</font>) and JA Solar (<a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a>) are <a href=\"https://thefly.com/thestreet/realmoney/index.php/JKSid2740203/JKS-Correction-JinkoSolar-downgraded-to-Sell-from-Neutral-at-Roth-Capital\" target=\"_blank\">downgraded to Sell</a> from Neutral, and Amtech Systems (<a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a> <font color='red'>-13.7%</font>) and Daqo New Energy (<a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-21.7%</font>) are cut to Neutral, at Roth Capital after China's government released its Solar Management Plan, which the firm believes is \"much worse than expected\" and will result in a \"massive\" net oversupply of cell capacity.</li>     <li>Given <a href=\"https://seekingalpha.com/news/3361388-solar-stocks-slammed-china-imposes-new-restrictions\" target=\"_blank\">China's new policy</a>, the outlook for module ASPs has \"suddenly deteriorated\" for both 2018 and 2019, Roth's Philip Shen says; on JASO, while its merger deal was approved, Shen sees risk to the shares if the agreement is not successfully completed.</li>     <li>Shen believes the outlook for additional orders for ASYS has deteriorated for 2018 and 2019 and foresees a similar scenario for polysilicon prices, and DQ shares should suffer as poly pricing falls.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361444\" data-linked=\"Several solar stocks cut at Roth on &#39;worse than expected&#39; new China policy\" data-tweet=\"$JKS $JKS $JASO - Several solar stocks cut at Roth on &#39;worse than expected&#39; new China policy https://seekingalpha.com/news/3361444-several-solar-stocks-cut-roth-on-worse-expected-new-china-policy?source=tweet\" data-url=\"https://seekingalpha.com/news/3361444-several-solar-stocks-cut-roth-on-worse-expected-new-china-policy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361438\" data-ts=\"1528128063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABAC-OLD\" target=\"_blank\">ABAC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361438-consumer-top-gainers-losers-of-12-00-pm-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (06/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='green'>+43%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361438\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (06/04/2018)\" data-tweet=\"$ABAC-OLD $ABAC-OLD $SGOC - Consumer - Top Gainers / Losers as of 12:00 PM (06/04/2018) https://seekingalpha.com/news/3361438-consumer-top-gainers-losers-of-12-00-pm-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361438-consumer-top-gainers-losers-of-12-00-pm-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361437\" data-ts=\"1528127766\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHP\" target=\"_blank\">BHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361437-copper-moves-higher-traders-watch-labor-talks-on-bhps-escondida\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Copper moves higher as traders watch labor talks on BHP&#39;s Escondida</a></h4><ul>     <li><a href=\"https://www.wsj.com/articles/metals-copper-rises-as-traders-watch-labor-negotiations-1528124952\" target=\"_blank\">Comex copper climbs ~1%</a> to $3.13/lb. as BHP&nbsp;Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-0.1%</font>) <a href=\"https://seekingalpha.com/news/3361154-bhp-says-escondida-mine-workers-start-new-wage-talks\" target=\"_blank\">resumes contract negotiations</a> with workers at its Escondida copper mine in Chile a year after a 44-day strike lifted prices.</li>     <li>&ldquo;Given the aggressive stance of the unions from the start of these talks, their bonus claims would break records for the Chilean industry,&rdquo; which may prompt investors &ldquo;to gather up additional inventory while they still can,&rdquo; says Investec analyst Hunter Hillcoat.</li>     <li>Copper prices have fallen ~5% YTD after hitting a nearly four-year high late in December, and &ldquo;the metal has struggled to break higher on every attempt in the last few months,&rdquo; says Marex Spectron's Dee Perera.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/CUPM' title='iPath Pure Beta Copper ETN'>CUPM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3361437\" data-linked=\"Copper moves higher as traders watch labor talks on BHP&#39;s Escondida\" data-tweet=\"$BHP $BHP $JJCTF - Copper moves higher as traders watch labor talks on BHP&#39;s Escondida https://seekingalpha.com/news/3361437-copper-moves-higher-traders-watch-labor-talks-on-bhps-escondida?source=tweet\" data-url=\"https://seekingalpha.com/news/3361437-copper-moves-higher-traders-watch-labor-talks-on-bhps-escondida\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361436\" data-ts=\"1528127728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361436-snapplus-6_1-information-suggests-stake-sale-happen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap +6.1%; The Information suggests stake sale could happen</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is making a sharp move higher today, <font color='green'>up 6.1%</font> and at its highest point in over a month, and pressing for its fourth straight day of gains.</li>    <li>Key news today is a suggestion from The Information about how the company can deal with a heavy cash burn: It's spend $1.1B over five quarters and has about $1.8B left to tap.</li>    <li>The article speculates that Snap could <a href=\"https://www.theinformation.com/articles/why-snap-should-tap-apple-or-tencent-for-cash\" target=\"_blank\">sell a stake for cash</a>, perhaps to Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a>), which already holds a stake in the company.</li>    <li>But the article suggests the company could even head to Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>), Amazon.com (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) or Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>), and cites a <a href=\"https://seekingalpha.com/filing/4000619\" target=\"_blank\">May 1 shelf registration</a> as evidence that it could happen.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361436\" data-linked=\"Snap +6.1%; The Information suggests stake sale could happen\" data-tweet=\"$SNAP $SNAP $TCEHY - Snap +6.1%; The Information suggests stake sale could happen https://seekingalpha.com/news/3361436-snapplus-6_1-information-suggests-stake-sale-happen?source=tweet\" data-url=\"https://seekingalpha.com/news/3361436-snapplus-6_1-information-suggests-stake-sale-happen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>75&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361433\" data-ts=\"1528127157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361433-fossil-jumps-to-52-week-high-on-keybanc-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fossil jumps to 52-week high on KeyBanc confidence</a></h4><ul> <li>Fossil (<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+8.1%</font>) races higher after KeyBanc hikes its price target on the retailer to a Street-high&nbsp;<a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Fossil+%28FOSL%29+PT+Raised+to+%2432+at+KeyBanc%2C+Believes+Business+has+Taken+a+Turn+for+Better/14265511.html\" target=\"_blank\">$32</a>.</li> <li>KeyBanc thinks Fossil is in a solid position to be the number two player in the wearables market and sees the overall business as taking a turn for the better.</li> <li>Fossil carved out a new 52-week high of $26.24 earlier in the day.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3361433\" data-linked=\"Fossil jumps to 52-week high on KeyBanc confidence\" data-tweet=\"$FOSL - Fossil jumps to 52-week high on KeyBanc confidence https://seekingalpha.com/news/3361433-fossil-jumps-to-52-week-high-on-keybanc-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3361433-fossil-jumps-to-52-week-high-on-keybanc-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361430\" data-ts=\"1528127126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPMI\" target=\"_blank\">SPMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361430-speedemissions-jumps-33-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Speedemissions jumps 33% post Q1 results</a></h4><ul><li>Speedemissions (<a href='https://seekingalpha.com/symbol/SPMI' title='Speedemissions, Inc.'>OTCPK:SPMI</a> <font color='green'>+33.3%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/17181663-speedemissions-inc-announces-first-quarter-2018-financial-results\" target=\"_blank\">reports      Q</a><a href=\"https://seekingalpha.com/pr/17181663-speedemissions-inc-announces-first-quarter-2018-financial-results\" target=\"_blank\">1</a>&nbsp;revenue decrease of 2% Y/Y to $879.6K, this decline in revenue is      attributed solely to the loss of the lease of the&nbsp;Salt Lake City&nbsp;store.</li><li>Overall same store sales increased $21.7K or 2.6%, with&nbsp;Atlanta&nbsp;up      2.4% and&nbsp;St. Louis&nbsp;up 4.9%.</li><li>Due to a reduction in legal, accounting,      professional fees and salary expenses, store operating expenses were down      3.7% Y/Y to $19K, and G&amp;A expenses were down 27.8% Y/Y to $57K.</li><li>Net profit was $30.2K (-87.7% Y/Y), this net      profit adjustment was because of the gain on the disposal of non-strategic      assets from the&nbsp;Utah&nbsp;store closing and the de-recognition of aged      accounts payable for Q1 2017.</li><li>Current liabilities of $1.3M (-11.1% Y/Y).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361399-speedemissions-reports-q1-results\" target=\"_blank\">Speedemissions reports Q1 results</a> (June 4)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361430\" data-linked=\"Speedemissions jumps 33% post Q1 results\" data-tweet=\"$SPMI - Speedemissions jumps 33% post Q1 results https://seekingalpha.com/news/3361430-speedemissions-jumps-33-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3361430-speedemissions-jumps-33-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361431\" data-ts=\"1528126963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361431-variety-twitter-disbands-video-unit-to-reorganize-efforts-regionally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Variety: Twitter disbands video unit to reorganize efforts regionally</a></h4><ul>   <li>Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='green'>+2%</font>) has disbanded its live-video business unit and <a href=\"https://variety.com/2018/digital/news/twitter-content-restructuring-live-video-strategy-1202829206/\" target=\"_blank\">reconsolidated those functions</a> as part of a content reorganization, <i>Variety</i> reports.</li>    <li>The video unit that was responsible for deals with Disney/ESPN, Major League Baseball and BuzzFeed will have its functions appear under Kay Madati, the company's global head of content partnerships, in a more regional structure rather than one based on categories.</li>    <li>Executives in five regions (U.S.; Latin America/Canada; EMEA; Japan/Korea; and Asia-Pacific) will run global content partnerships for Madati.</li>    <li>The move means Twitter's former head of global news, Peter Greenberger, is leaving, as is Todd Swidler, the former Bloomberg Media exec hired a year ago to lead Twitter's live-video group.</li>    <li>The regional focus doesn't portend a move away from video -- the company announced 30 new or expanded video deals at NewFronts -- but could show internal discord over how to proceed.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361431\" data-linked=\"Variety: Twitter disbands video unit to reorganize efforts regionally\" data-tweet=\"$TWTR - Variety: Twitter disbands video unit to reorganize efforts regionally https://seekingalpha.com/news/3361431-variety-twitter-disbands-video-unit-to-reorganize-efforts-regionally?source=tweet\" data-url=\"https://seekingalpha.com/news/3361431-variety-twitter-disbands-video-unit-to-reorganize-efforts-regionally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361429\" data-ts=\"1528126583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361429-five-below-rallies-after-jpmorgan-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below rallies after JPMorgan upgrade</a></h4><ul> <li>JPMorgan dials up an Overweight rating for Five Below (<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a> <font color='green'>+6.5%</font>) on confidence the retailer will see annual net income growth of over 20%.</li> <li>The firm points to Five Below's strong store unit growth and positive traffic trends at existing stores.</li> <li>JP's price target of $87 reps almost 20% upside for shares.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3361429\" data-linked=\"Five Below rallies after JPMorgan upgrade\" data-tweet=\"$FIVE - Five Below rallies after JPMorgan upgrade https://seekingalpha.com/news/3361429-five-below-rallies-after-jpmorgan-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3361429-five-below-rallies-after-jpmorgan-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361428\" data-ts=\"1528126547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361428-gilead-up-1-on-reported-settlement-mylan-over-tybost-encouraging-news-on-new-cancer-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead up 1% on reported settlement with Mylan over Tybost, encouraging news on new cancer treatment</a></h4><ul><li>Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+1.4%</font>) perks up on below-average volume in apparent response to <a href=\"https://twitter.com/RVH_Investing/status/1003657757931778048\" target=\"_blank\">chatter </a>that it is nearing a settlement with Mylan NV (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-1.1%</font>) in a patent infringement dispute regarding Tybost (cobicistat). Gilead <a href=\"https://insight.rpxcorp.com/litigation_documents/11918466\" target=\"_blank\">sued </a>Mylan a couple of years ago in response to its filing for a generic version of the HIV med.</li><li><strong>Update</strong>: Another bit of good news is a Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2018-06-04/billions-of-fighting-cells-clear-woman-s-breast-cancer-in-study\" target=\"_blank\">report </a>that an experimental cell therapy from its Kite Pharma unit eradicated breast cancer in a 49 year-old woman with tennis ball-sized tumors in her liver that was progressing despite seven types of chemo and hormonal therapy.</li><li>It took about eight weeks to craft the therapy for the patient after removing tumor-infiltrating lymphocytes from a tissue biopsy. Six week after infusion, her cancer had shrunk by 50% and was completely gone 2 1/2 years later.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361428\" data-linked=\"Gilead up 1% on reported settlement with Mylan over Tybost, encouraging news on new cancer treatment\" data-tweet=\"$GILD $GILD $MYL - Gilead up 1% on reported settlement with Mylan over Tybost, encouraging news on new cancer treatment https://seekingalpha.com/news/3361428-gilead-up-1-on-reported-settlement-mylan-over-tybost-encouraging-news-on-new-cancer-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3361428-gilead-up-1-on-reported-settlement-mylan-over-tybost-encouraging-news-on-new-cancer-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361423\" data-ts=\"1528126010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTN\" target=\"_blank\">GTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361423-stephens-sees-better-second-half-for-local-broadcasting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stephens sees better second half for local broadcasting</a></h4><ul>   <li>Concerns should start to lighten for broadcast TV firms in the second half of the year, Stephens says, despite the ongoing challenge of softness in core advertising.</li>    <li>But even ads will get a break as auto ad spending levels out and midterm elections provide a political boost, analyst Kyle Evans notes. (h/t Bloomberg)</li>    <li>It's bullish on most firms in the field, though Nexstar (<a href=\"http://seekingalpha.com/symbol/NXST\" target=\"_blank\">NXST</a> <font color='red'>-0.5%</font>) is its top pick in traditional media with a price target of $84, implying 26% upside. On the other hand, it's trimmed its price target for Meredith (<a href=\"http://seekingalpha.com/symbol/MDP\" target=\"_blank\">MDP</a> <font color='red'>-1.7%</font>) to $56 from $60 (13.8% upside from current pricing) while it watches for improving revenue trends in its National Media Group.</li>    <li>The firm's also Overweight on Gray Television (<a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a> <font color='red'>-0.2%</font>, with a price target of $19) and Tegna (<a href='https://seekingalpha.com/symbol/TGNA' title='TEGNA'>TGNA</a> <font color='green'>+0.9%</font>, with a price target of $14).</li>    <li>The industry also gets a benefit from more clarity on Sinclair Broadcast Group's (<a href=\"http://seekingalpha.com/symbol/SBGI\" target=\"_blank\">SBGI</a> <font color='green'>+0.5%</font>) deal for Tribune Media (<a href=\"http://seekingalpha.com/symbol/TRCO\" target=\"_blank\">TRCO</a> <font color='red'>-0.3%</font>); Sinclair should gain in the second half as well once the deal closes, Evans notes, rating it Overweight with a price target of $47.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361423\" data-linked=\"Stephens sees better second half for local broadcasting\" data-tweet=\"$GTN $GTN $TGNA - Stephens sees better second half for local broadcasting https://seekingalpha.com/news/3361423-stephens-sees-better-second-half-for-local-broadcasting?source=tweet\" data-url=\"https://seekingalpha.com/news/3361423-stephens-sees-better-second-half-for-local-broadcasting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361417\" data-ts=\"1528125785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361417-shire-down-2-on-prucalopride-cv-safety-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire down 2% on prucalopride CV safety data</a></h4><ul><li>Shire plc (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='red'>-2%</font>) slips on below-average volume in response to cardiovascular&nbsp; &#40;CV&#41; <a href=\"https://seekingalpha.com/pr/17180846-shire-plc-new-data-cardiovascular-safety-prucalopride-presented-2018-digestive-disease-week\" target=\"_blank\">safety data</a> on chronic ideopathic constipation &#40;CIC&#41; med prucalopride, a serotonin type 4 (5-HT4) receptor agonist. The results were presented at the Digestive Disease Week Annual Meeting in Washington, DC.</li><li>A pooled analysis of over 35K patients with chronic constipation who were new users of prucalopride or polyethylene glycol &#40;PEG&#41; showed no overall increase in major adverse cardiovascular events &#40;MACE&#41; in patients receiving prucalopride compared to PEG.</li><li>Alicia Gilsenan, Ph.D., Senior Director, Epidemiology, RTI Health Solutions, says,\"Because prior 5-HT4 agonists have been associated with adverse cardiovascular events in the past, further evaluating the risk of MACE in patients taking prucalopride was important. Findings from this cohort study have provided us with real-world evidence from a large patient population about the cardiovascular safety profile of prucalopride compared with polyethylene glycol.\"</li><li>The company's U.S. marketing application is currently under FDA review with an action date of December 21.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3336423-fda-accepts-shires-marketing-application-cic-med-prucalopride-action-date-december-21\" target=\"_blank\">FDA accepts Shire's marketing application for CIC med prucalopride, action date December 21</a> (March 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361417\" data-linked=\"Shire down 2% on prucalopride CV safety data\" data-tweet=\"$SHPG - Shire down 2% on prucalopride CV safety data https://seekingalpha.com/news/3361417-shire-down-2-on-prucalopride-cv-safety-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3361417-shire-down-2-on-prucalopride-cv-safety-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361406\" data-ts=\"1528124612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDB\" target=\"_blank\">MDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361406-needham-raises-mongodb-target-to-12-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham raises MongoDB target to 12% upside</a></h4><ul><li>        Needham raises its MongoDB (NASDAQ:<a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a>) price target from $43 to $52 (12% upside to Friday&rsquo;s close) ahead of the earnings report on Wednesday.</li><li>               Needham expects a strong quarter driven by broad industry checks revealing robust demand.&nbsp;</li><li>               Source: Briefing.com. &nbsp;&nbsp;</li><li>               MongoDB shares are&nbsp;<font color='green'>up 1.03%</font>&nbsp;to $47.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3361406\" data-linked=\"Needham raises MongoDB target to 12% upside\" data-tweet=\"$MDB - Needham raises MongoDB target to 12% upside https://seekingalpha.com/news/3361406-needham-raises-mongodb-target-to-12-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3361406-needham-raises-mongodb-target-to-12-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361404\" data-ts=\"1528124463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361404-healthcare-top-5-gainers-losers-of-11-00-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CWBR' title='CohBar Inc.'>CWBR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/DNLI' title='Denali Therapeutics, Inc.'>DNLI</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/GTHX' title='G1 Therapeutics'>GTHX</a> <font color='red'>-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361404\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/04/2018)\" data-tweet=\"$DCPH $DCPH $AVXL - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/04/2018) https://seekingalpha.com/news/3361404-healthcare-top-5-gainers-losers-of-11-00-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361404-healthcare-top-5-gainers-losers-of-11-00-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361403\" data-ts=\"1528124390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMTL\" target=\"_blank\">CMTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361403-comtech-adds-3_7m-modification-to-army-bftminus-2-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comtech adds $3.7M modification to Army BFT-2 contract</a></h4><ul>   <li>Comtech Telecommunications' (<a href=\"http://seekingalpha.com/symbol/CMTL\" target=\"_blank\">CMTL</a> <font color='green'>+1.9%</font>) Maryland unit has added a new multimillion-dollar <a href=\"https://seekingalpha.com/pr/17181464-comtech-receives-3_7-million-funding-support-bftminus-2-program\" target=\"_blank\">contract modification</a> to the company's government solutions revenue stream.</li>    <li>The Comtech Mobile Datacom Corp. has gotten a $3.7M modification from Consortium Management Group to support the Army's Blue Force Tracking 2 program.</li>    <li>That provides funding for a Phase 1B (which with Phase 1 totals $5M); the total value including a Phase 2 and 3 execution is $6.5M.</li>    <li>BFT-2 is a second-generation system designed to provide Situational Awareness and Command &amp; Control messaging to military platforms.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361403\" data-linked=\"Comtech adds $3.7M modification to Army BFT-2 contract\" data-tweet=\"$CMTL - Comtech adds $3.7M modification to Army BFT-2 contract https://seekingalpha.com/news/3361403-comtech-adds-3_7m-modification-to-army-bftminus-2-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3361403-comtech-adds-3_7m-modification-to-army-bftminus-2-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361402\" data-ts=\"1528124209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361402-suntrust-raises-amazon-target-to-22-upside-on-private-label-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust raises Amazon target to 22% upside on private label potential</a></h4><ul><li>        SunTrust <a href=\"https://www.cnbc.com/2018/06/04/suntrust-amazons-private-label-business-to-help-stock-rally-20-percent.html\" target=\"_blank\">raises</a> its Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) price target from $1,900 to $2,000, a 22% upside to Friday&rsquo;s close.</li><li>               Analyst Youssef Squali expects Amazon&rsquo;s private label business to generate $25B in revenue by 2022, up 108% from SunTrust&rsquo;s $3.6B estimate for 2017.&nbsp;</li><li>               Squali: \"As strong an e-commerce platform as Amazon has become over the last 20 years, we believe that the best has yet to come. Private label is one of the highly under appreciated trends within Amazon, in our view, which over time should give the company a strong 'unfair' competitive advantage. 'Unfair' because it'll be very difficult to dislodge the company once it attains it; fair because it's earned, not bestowed.\"&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 0.5%</font>&nbsp;to $1,650.32.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3361402\" data-linked=\"SunTrust raises Amazon target to 22% upside on private label potential\" data-tweet=\"$AMZN - SunTrust raises Amazon target to 22% upside on private label potential https://seekingalpha.com/news/3361402-suntrust-raises-amazon-target-to-22-upside-on-private-label-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3361402-suntrust-raises-amazon-target-to-22-upside-on-private-label-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361401\" data-ts=\"1528124027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTI\" target=\"_blank\">PSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361401-pluristem-up-6-ahead-of-plx-pad-data-readout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluristem up 6% ahead of PLX-PAD data readout</a></h4><ul><li>Thinly traded micro cap Pluristem (<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a> <font color='green'>+5.9%</font>) is up on more than a 4x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/17180978-pluristem-announce-top-line-results-multinational-phase-ii-intermittent-claudication-study\" target=\"_blank\">announcement </a>that it will release topline data from its Phase 2 clinical trial assessing PLX-PAD cells in intermittent claudication &#40;IC&#41; on Tuesday, June 12. IC, a subset of peripheral artery disease, is caused by restricted blood flow in the legs leading to muscle pain, cramping, numbness and a sense of fatigue, commonly in the calf muscle.</li><li>The primary endpoint is the change in maximum walking distance one year after the first treatment with PLX-PAD.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234850-pluristem-completes-enrollment-mid-stage-study-plx-pad-cells-peripheral-arterydisease\" target=\"_blank\">Pluristem completes enrollment in mid-stage study of PLX-PAD cells in peripheral arterydisease</a> (Jan. 12, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361401\" data-linked=\"Pluristem up 6% ahead of PLX-PAD data readout\" data-tweet=\"$PSTI - Pluristem up 6% ahead of PLX-PAD data readout https://seekingalpha.com/news/3361401-pluristem-up-6-ahead-of-plx-pad-data-readout?source=tweet\" data-url=\"https://seekingalpha.com/news/3361401-pluristem-up-6-ahead-of-plx-pad-data-readout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361387\" data-ts=\"1528123141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AETI\" target=\"_blank\">AETI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361387-american-electric-jolts-141-on-14m-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Electric jolts 141% on $14M project</a></h4><ul><li>American Electric's (<a href='https://seekingalpha.com/symbol/AETI' title='American Electric Technologies, Inc.'>AETI</a> <font color='green'>+141.9%</font>) M&amp;I Electric business has been <a href=\"https://seekingalpha.com/pr/17181496-m-electric-announces-14m-project-leading-epc-firm\" target=\"_blank\">awarded</a> a $14M contract from an EPC firm, to provide a turnkey power delivery solution for a fractionation plant expansion project in Texas.</li><li>The EPC firm is responsible for the design and delivery of this project to expand fractionation capacity for their midstream project customer.</li><li>\"This project award is one of the largest in the company&rsquo;s history and is further validation of our strategy to be a leading provider of safe, intelligent arc-resistant switchgear and turnkey Power Distribution Center solutions for the midstream and downstream oil and gas markets&rdquo;, said CEO Charles Dauber.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361387\" data-linked=\"American Electric jolts 141% on $14M project\" data-tweet=\"$AETI $SLNG - American Electric jolts 141% on $14M project https://seekingalpha.com/news/3361387-american-electric-jolts-141-on-14m-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3361387-american-electric-jolts-141-on-14m-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361391\" data-ts=\"1528122604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDRA\" target=\"_blank\">IDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361391-idera-pharma-down-11-despite-encouraging-tilsotolimod-data-in-melanoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idera Pharma down 11% despite encouraging tilsotolimod data in melanoma</a></h4><ul><li>Investors appear disappointed with <a href=\"https://seekingalpha.com/pr/17181149-idera-pharmaceuticals-presents-clinical-data-illuminateminus-204-trial-combination\" target=\"_blank\">interim data</a> from a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02644967?titles=illuminate-204&amp;spons=idera&amp;rank=1\" target=\"_blank\">ILLUMINATE-204</a>, assessing Idera Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='red'>-10.7%</font>) tilsotolimod in metastatic melanoma patients who failed to respond to PD-1 inhibitor therapy. The results were presented at ASCO in Chicago.</li><li>The overall response rate was 38% (n=8/21), including two complete responses, in advanced melanoma patients receiving the combination of tilsotolimod, an intratumorally administered toll-like receptor 9 agonist, and Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-4.4%</font>) Yervoy (ipilimumab) after switching from Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+2.2%</font>) Keytruda (pembrolizumab). The ORR was only 13% in patients who switched to Yervoy alone. Median duration of response has not been reached. The disease control rate (responders + stable cancer) was 71% (n=15/21).</li><li>Enrollment of up to 60 subjects should be completed by year-end.</li><li>A Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03445533?titles=illuminate-301&amp;spons=idera&amp;rank=1\" target=\"_blank\">ILLUMINATE-301</a>, assessing tilsotolimod + ipilimumab compared to ipilimumab alone in anti-PD-1-refractory melanoma was launched last quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361391\" data-linked=\"Idera Pharma down 11% despite encouraging tilsotolimod data in melanoma\" data-tweet=\"$IDRA $IDRA $BMY - Idera Pharma down 11% despite encouraging tilsotolimod data in melanoma https://seekingalpha.com/news/3361391-idera-pharma-down-11-despite-encouraging-tilsotolimod-data-in-melanoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3361391-idera-pharma-down-11-despite-encouraging-tilsotolimod-data-in-melanoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361388\" data-ts=\"1528122024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DQ\" target=\"_blank\">DQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361388-solar-stocks-slammed-china-imposes-new-restrictions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solar stocks slammed as China imposes new restrictions</a></h4><ul>     <li>Solar shares are broadly lower after the government moved to rein in overcapacity in the industry by <a href=\"http://www.scmp.com/business/companies/article/2149131/chinese-solar-power-stocks-plunge-government-moves-contain\" target=\"_blank\">cutting subsidies and suspending the construction of new farms</a>.</li>     <li>Chinese regulators announced Friday that the allocation of quotas for new projects had been halted until further notice, and tariffs on electricity generated from clean energy would be lowered by 0.05 yuan/kwh, a 6.7%-9% reduction depending on the region, effective June 1.</li>     <li>The measures are aimed at &ldquo;promoting the solar energy sector&rsquo;s  sustainable development, enhancing its development quality and speeding  up reduction of subsidies.\"</li>     <li>Among relevant tickers: <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-20.5%</font>, <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-15.2%</font>, <a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-10.6%</font>, <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='red'>-10.5%</font>, <a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd.'>SOL</a> <font color='red'>-5.1%</font>, <a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='red'>-4.9%</font>, <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='red'>-4.5%</font>, <a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='red'>-2.6%</font>, <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-2.4%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a>, <a href='https://seekingalpha.com/symbol/KWT' title='VanEck Vectors Solar Energy ETF'>KWT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3361388\" data-linked=\"Solar stocks slammed as China imposes new restrictions\" data-tweet=\"$DQ $DQ $JKS - Solar stocks slammed as China imposes new restrictions https://seekingalpha.com/news/3361388-solar-stocks-slammed-china-imposes-new-restrictions?source=tweet\" data-url=\"https://seekingalpha.com/news/3361388-solar-stocks-slammed-china-imposes-new-restrictions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>104&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361383\" data-ts=\"1528121456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IQ\" target=\"_blank\">IQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361383-iqiyiplus-1_4-no-clear-catalyst\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IQiyi +1.4% with no clear catalyst</a></h4><ul><li>        IQiyi (NASDAQ:<a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc'>IQ</a>) shares are<font color='green'> up 1.4%</font>&nbsp;to $28.86 with no clear catalyst.</li><li>               IQiyi shares are&nbsp;<font color='green'>up 24%</font>&nbsp;in the past week and&nbsp;<font color='green'>up 64.5%</font>&nbsp;in the past month since the IPO in late March.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3361383\" data-linked=\"IQiyi +1.4% with no clear catalyst\" data-tweet=\"$IQ - IQiyi +1.4% with no clear catalyst https://seekingalpha.com/news/3361383-iqiyiplus-1_4-no-clear-catalyst?source=tweet\" data-url=\"https://seekingalpha.com/news/3361383-iqiyiplus-1_4-no-clear-catalyst\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361381\" data-ts=\"1528121016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JMU\" target=\"_blank\">JMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361381-jmuplus-4-no-clear-catalyst\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JMU +4% with no clear catalyst</a></h4><ul><li>        JMU (NASDAQ:<a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a>) shares are&nbsp;<font color='green'>up 4%</font>&nbsp;to $0.53 with no clear catalyst.</li><li>               JMU shares are&nbsp;<font color='red'>down 19.1%</font>&nbsp;in the past week,&nbsp;<font color='red'>12.4%</font>&nbsp;in the past month, and&nbsp;<font color='red'>50%</font>&nbsp;YTD. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3361381\" data-linked=\"JMU +4% with no clear catalyst\" data-tweet=\"$JMU - JMU +4% with no clear catalyst https://seekingalpha.com/news/3361381-jmuplus-4-no-clear-catalyst?source=tweet\" data-url=\"https://seekingalpha.com/news/3361381-jmuplus-4-no-clear-catalyst\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361376\" data-ts=\"1528120671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QLYS\" target=\"_blank\">QLYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361376-qualys-announces-intent-to-purchase-cybersecurity-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualys announces intent to purchase cybersecurity company</a></h4><ul><li>        Qualys (NASDAQ:<a href='https://seekingalpha.com/symbol/QLYS' title='Qualys'>QLYS</a>) announces entering a non-binding letter of intent to purchase cybersecurity company Second Front Systems.</li><li>               The parties need to negotiate and enter into definitive agreements before proceeding with the acquisition.&nbsp;</li><li>               Qualys shares are&nbsp;<font color='red'>down 0.9%</font>&nbsp;to $77.42. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3361376\" data-linked=\"Qualys announces intent to purchase cybersecurity company\" data-tweet=\"$QLYS - Qualys announces intent to purchase cybersecurity company https://seekingalpha.com/news/3361376-qualys-announces-intent-to-purchase-cybersecurity-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3361376-qualys-announces-intent-to-purchase-cybersecurity-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361371\" data-ts=\"1528120128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361371-immunomedics-and-clovis-oncology-team-up-in-tnbc-urothelial-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunomedics and Clovis Oncology team up in TNBC/urothelial cancer study</a></h4><ul><li>Immunomedics (<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+12.2%</font>) and Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='green'>+0.2%</font>) will <a href=\"https://seekingalpha.com/pr/17180858-clovis-oncology-immunomedics-announce-planned-clinical-collaboration-study-combination\" target=\"_blank\">collaborate </a>in a Phase 1/2 clinical trial assessing the combination of antibody-drug conjugate sacituzumab govitecan and Rubraca (rucaparib) in patients with metastatic triple-negative breast cancer (mTNBC) and metastatic urothelial cancer (mUC).</li><li>After the completion of the initial safety phase, the cohort will be expanded into mTNBC and mUC arms.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361366-immunomedics-sacituzumab-govitecan-shows-positive-action-breast-cancer-study-shares-8-percent\" target=\"_blank\">Immunomedics' sacituzumab govitecan shows positive action in breast cancer study; shares up 8%</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361371\" data-linked=\"Immunomedics and Clovis Oncology team up in TNBC/urothelial cancer study\" data-tweet=\"$IMMU $IMMU $CLVS - Immunomedics and Clovis Oncology team up in TNBC/urothelial cancer study https://seekingalpha.com/news/3361371-immunomedics-and-clovis-oncology-team-up-in-tnbc-urothelial-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3361371-immunomedics-and-clovis-oncology-team-up-in-tnbc-urothelial-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361366\" data-ts=\"1528119488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361366-immunomedics-sacituzumab-govitecan-shows-positive-action-in-breast-cancer-study-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunomedics&#39; sacituzumab govitecan shows positive action in breast cancer study; shares up 8%</a></h4><ul><li>Immunomedics (<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+8.1%</font>) is up in early trade in response to its <a href=\"https://seekingalpha.com/pr/17180834-immunomedics-reveals-promising-data-sacituzumab-govitecan-patients-heavily-pretreated\" target=\"_blank\">announcement</a> of positive results from a Phase 1/2 clinical trial assessing antibody-drug conjugate &#40;ADC&#41; sacituzumab govitecan in patients with ER-positive/HER2-negative metastatic breast cancer who had received at least two prior lines of therapy. The data were presented at ASCO in Chicago.</li><li>The overall response rate was 31.5% (n=17/54). Median duration of response was 7.4 months. The disease control rate (responders + stable cancer) was 48.1% (n=26/54).</li><li>The company is currently seeking guidance from regulatory authorities on a potential registration pathway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361366\" data-linked=\"Immunomedics&#39; sacituzumab govitecan shows positive action in breast cancer study; shares up 8%\" data-tweet=\"$IMMU - Immunomedics&#39; sacituzumab govitecan shows positive action in breast cancer study; shares up 8% https://seekingalpha.com/news/3361366-immunomedics-sacituzumab-govitecan-shows-positive-action-in-breast-cancer-study-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3361366-immunomedics-sacituzumab-govitecan-shows-positive-action-in-breast-cancer-study-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361369\" data-ts=\"1528119453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361369-discovery-seals-2b-12-year-deal-for-international-pga-tour-rights\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery seals $2B 12-year deal for international PGA Tour rights</a></h4><ul>   <li>Discovery (<a href=\"http://seekingalpha.com/symbol/DISCA\" target=\"_blank\">DISCA</a> <font color='green'>+1.9%</font>) has agreed to pay $2B to get 12-year international TV and online rights to the PGA Tour.</li>    <li>The deal, which runs from 2019 through 2030, includes global TV and multi-platform live rights to all the Tour's media properties, and also provides for a new over-the-top streaming service.</li>    <li>That provides for about 2,000 hours a year of premium content, the company says, including six tours under PGA Tour's umbrella and nearly 150 tournaments a year.</li>    <li>Discovery will leverage its experience with Eurosport Player in establishing the PGA Tour-branded streaming service.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361369\" data-linked=\"Discovery seals $2B 12-year deal for international PGA Tour rights\" data-tweet=\"$DISCA $DISCB $DISCK - Discovery seals $2B 12-year deal for international PGA Tour rights https://seekingalpha.com/news/3361369-discovery-seals-2b-12-year-deal-for-international-pga-tour-rights?source=tweet\" data-url=\"https://seekingalpha.com/news/3361369-discovery-seals-2b-12-year-deal-for-international-pga-tour-rights\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361368\" data-ts=\"1528119416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361368-microsoft-acquires-github-for-7_5b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft acquires GitHub for $7.5B</a></h4><ul><li>        Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) <a href=\"https://seekingalpha.com/pr/17181581-microsoft-acquire-github-7_5-billion\" target=\"_blank\">acquires</a> code-repository platform GitHub for $7.5B in Microsoft stock.</li><li>               Microsoft VP Nat Friedman will assume the role of Github CEO while current Github leader Chris Wanstrath becomes a Microsoft technical fellow.&nbsp;</li><li>                  The deal is expected to close by the end of CY18. Upon closing, GitHub&rsquo;s financials will be reported as part of Microsoft&rsquo;s Intelligent Cloud segment.    </li><li>               Microsoft expects the acquisition to be accretive to non-GAAP operating income in FY20 and to have a dilution of less than 1% to non-GAAP EPS in FY19 and FY20. &nbsp;&nbsp;</li><li>               Conference call: The related parties will have a joint conference call today at 10 AM Eastern to discuss the transaction with a webcast available <a href=\"https://edge.media-server.com/m6/p/eudfciq3\" target=\"_blank\">here</a>.&nbsp;</li><li>                  Microsoft shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;to $101.66.&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3361183-business-insider-microsoft-talks-acquire-github\" target=\"_blank\">Business Insider: Microsoft in talks to acquire GitHub</a> (June 1)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361311-bloomberg-microsoft-announce-github-acquisition-today\" target=\"_blank\">Bloomberg: Microsoft could announce GitHub acquisition today</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3361368\" data-linked=\"Microsoft acquires GitHub for $7.5B\" data-tweet=\"$MSFT - Microsoft acquires GitHub for $7.5B https://seekingalpha.com/news/3361368-microsoft-acquires-github-for-7_5b?source=tweet\" data-url=\"https://seekingalpha.com/news/3361368-microsoft-acquires-github-for-7_5b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361362\" data-ts=\"1528118816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTDOY\" target=\"_blank\">NTDOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361362-ntdoyminus-7-jefferies-blames-technicals-for-nintendo-slump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NTDOY -7%; Jefferies blames technicals for Nintendo slump</a></h4><ul>   <li>Nintendo ADRs (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd. ADR'>OTCPK:NTDOY</a>) are <font color='red'>7.1% lower</font> in premarket U.S. trading after the company's biggest tumble on Japanese markets in a year and a half.</li>    <li>Shares are slumping ahead of E3 and while observers are looking for what to blame, Jefferies thinks it's technical: The stock had stayed above its 200-day moving average since <i>Pokemon Go</i> in 2016, until last week. The firm's still advising a Buy with earnings, cash flow and dividends getting stronger. (h/t Bloomberg)</li>    <li>It's <font color='red'>down more than 12%</font> since March 26.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361362\" data-linked=\"NTDOY -7%; Jefferies blames technicals for Nintendo slump\" data-tweet=\"$NTDOY - NTDOY -7%; Jefferies blames technicals for Nintendo slump https://seekingalpha.com/news/3361362-ntdoyminus-7-jefferies-blames-technicals-for-nintendo-slump?source=tweet\" data-url=\"https://seekingalpha.com/news/3361362-ntdoyminus-7-jefferies-blames-technicals-for-nintendo-slump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361360\" data-ts=\"1528118774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361360-moviepass-owner-launching-film-studio\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoviePass owner launching film studio</a></h4><ul><li>           Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) <a href=\"https://www.businesswire.com/news/home/20180530005842/en/Helios-Matheson-Analytics-Launches-Moviepass-Films%E2%84%A2-Agrees\" target=\"_blank\">announces</a> receiving the exclusive option to acquire the film library and current production slate of EFO Films. </li><li> The EFO Films library includes releases like <i>Lone Survivor</i> and <i>Broken City </i>and upcoming titles including Boss Level starring Naomi Watts and Mel Gibson and The Irishman starring Robert De Niro and Al Pacino. <i>&nbsp;</i> </li><li> Helios also announces forming MoviePass Films with EFO Films with Helios holding a 51% stake and EFO holding the remaining stake. </li><li> The company says MoviePass Films will &ldquo;focus on studio-driven content and new film production for theatrical release and other distribution channels.&rdquo; </li><li> Helios and Matheson shares are&nbsp;<font color='green'>up 1%</font>&nbsp;premarket to $0.44.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3361360\" data-linked=\"MoviePass owner launching film studio\" data-tweet=\"$HMNY - MoviePass owner launching film studio https://seekingalpha.com/news/3361360-moviepass-owner-launching-film-studio?source=tweet\" data-url=\"https://seekingalpha.com/news/3361360-moviepass-owner-launching-film-studio\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361357\" data-ts=\"1528118599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSAR-OLD\" target=\"_blank\">VSAR-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361357-versartis-to-merge-aravive-biologics-shares-up-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Versartis to merge with Aravive Biologics; shares up 28% premarket</a></h4><ul><li>Thinly traded nano cap Versartis (NASDAQ:<a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a>) is up&nbsp;<font color='green'>28%</font>&nbsp;premarket on robust volume in response to its planned <a href=\"https://seekingalpha.com/pr/17181229-versartis-enters-merger-agreement-aravive-biologics-form-clinical-stage-biopharmaceutical\" target=\"_blank\">all-stock merger</a> with privately held <a href=\"http://aravive.com/\" target=\"_blank\">Aravive Biologics</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3361357\" data-linked=\"Versartis to merge with Aravive Biologics; shares up 28% premarket\" data-tweet=\"$VSAR-OLD - Versartis to merge with Aravive Biologics; shares up 28% premarket https://seekingalpha.com/news/3361357-versartis-to-merge-aravive-biologics-shares-up-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3361357-versartis-to-merge-aravive-biologics-shares-up-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3361354\" data-ts=\"1528118248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSAR-OLD\" target=\"_blank\">VSAR-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3361354-premarket-gainers-of-9-05-06-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (06/04/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a> <font color='green'>+28%</font>&nbsp;entered into a definitive <a href=\"https://seekingalpha.com/pr/17181229-versartis-enters-merger-agreement-aravive-biologics-form-clinical-stage-biopharmaceutical\" target=\"_blank\">agreement</a> with Aravive Biologics.</li>     <li><a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+15%</font>&nbsp;on LOXO-292 <a href=\"https://seekingalpha.com/news/3361324-loxo-oncology-15-percent-premarket-loxominus-292-data\" target=\"_blank\">data</a>.</li>     <li><a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+10%</font>&nbsp;on the <a href=\"https://seekingalpha.com/pr/17181427-size-launches-boxsizeid-measurement-technology-rugged-hand-held-devices-serve-343-billion\" target=\"_blank\">launch</a> of its BoxSizeID mobile measurement technology.</li>     <li><a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc'>PTN</a> <font color='green'>+8%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3361312-fda-accepts-palatin-technologies-nda-review-bremelanotide\" target=\"_blank\">accepts</a> NDA review for bremelanotide.</li>     <li><a href='https://seekingalpha.com/symbol/OCIP' title='OCI Partners, LP'>OCIP</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17181019-oci-partners-lps-board-directors-review-unsolicited-tender-offer-oci-n-v\" target=\"_blank\">offer</a> from OCI N.V.</li>     <li><a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17181138-chinanet-online-holdings-launches-first-blockchain-powered-mobile-application-intelligent\" target=\"_blank\">launching</a> first blockchain powered mobile application for intelligent marketing and advertising.</li>     <li><a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17181193-immunomedics-provides-business-update-asco-2018-investor-event\" target=\"_blank\">update</a> at the ASCO 2018 investor event.</li>     <li>PBR-A <font color='green'>+6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3361354\" data-linked=\"Premarket Gainers as of 9:05 am (06/04/2018)\" data-tweet=\"$VSAR-OLD $VSAR-OLD $LOXO - Premarket Gainers as of 9:05 am (06/04/2018) https://seekingalpha.com/news/3361354-premarket-gainers-of-9-05-06-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3361354-premarket-gainers-of-9-05-06-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}